Multispecific heavy chain antibodies having modified heavy chain constant regions

Abstract

Multispecific human heavy chain antibodies (e.g., UniAbs™) are provided that have modified heavy chain constant regions that confer advantageous properties. The invention further relates to methods for making such antibodies, compositions, such as pharmaceutical compositions, that comprise such antibodies, and their use to treat disorders characterized by expression of one or more of the binding targets described herein.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to the filing dates of U.S. Provisional Patent Application No. 63 / 017,589, filed April 29, 2020, and U.S. Provisional Patent Application No. 63 / 108,796, filed November 2, 2020, the disclosures of which are incorporated herein by reference in their entireties.

[0002] The present invention relates to multispecific human heavy chain antibodies (e.g., UniAbs™) having modified heavy chain constant regions that confer advantageous properties. The invention further relates to methods for making such antibodies, compositions, such as pharmaceutical compositions, comprising such antibodies, and their use to treat disorders characterized by expression of one or more of the binding targets described herein. [Background technology]

[0003] Modified Fc Region Advances in protein engineering have led to successful production and clinical use of multispecific antibodies with binding affinity to two or more targets. However, due to their heterodimeric nature, appropriate measures must be utilized to facilitate the appropriate pairing of the desired combination of binding sequences, and thus the polypeptide subunits, in the multispecific antibodies. Wang et al., mAbs 10:8,1226-1235(2018).

[0004] One approach to circumvent the problem of unpaired polypeptide subunits is known as "knobs-into-holes" (KiH), which aims to force pairing of two different antibody heavy chains by introducing mutations in the CH2 and / or CH3 domains to modify the contact interface. In one chain, bulky amino acids are replaced with amino acids with short side chains to create a "hole". Conversely, amino acids with large side chains are introduced into the other heavy chain to create a "knob". By co-expressing these two heavy chains, heterodimer formation ("knobs-holes") is observed in higher yields relative to homodimer formation ("holes-holes" or "knobs-knobs") due to the more favorable stability of the knob-hole pairing (Ridgway, JB, et al, Protein Eng. 9 (1996) 617-621; and WO 96 / 027011).

[0005] Although this strategy seems attractive to achieve the desired heterodimer, other properties of the resulting multispecific antibody depend heavily on the specific amino acid sequence of the Fc region, i.e., effector functions such as complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Furthermore, effector function activity can induce the production of cytokines, which can result in an unwanted inflammatory response "cytokine storm." Gupta et al., Journal of Interferon & Cytokine Research 40:1,19-23(2019). Thus, in certain situations, effector functions need to be reduced or completely eliminated, for example, to avoid damage or death of immune cells (e.g., T cells) to which the multispecific antibody binds, and / or to avoid unwanted cytokine production and the resulting unwanted inflammatory response.

[0006] Furthermore, the introduction of amino acid modifications into proteins can have significant drawbacks, namely the possibility of inducing an immune response by the patient against the protein based on the presence of non-native sequences. Therefore, the development of multispecific antibodies requires the identification of sequences that are highly similar in general structure to natural antibodies (IgA, IgD, IgE, IgG, IgM, etc.) and that have minimal deviations from the natural sequence, but at the same time successfully incorporate modifications that can achieve the goal of promoting the desired heterodimerization while also reducing or eliminating one or more effector functions.

[0007] To balance these competing requirements, we turned to IgG4 Fc, whose native sequence is known to have a relatively low level of effector function activity. Crescioli et al., Curr Allergy Asthma Rep 16:7 (2016). However, despite this apparent advantage, IgG4 is known to undergo chain exchange reactions in vivo due to its specific hinge region sequence, presenting additional complications in achieving the desired heterodimerization. Labrijn et al., Nature Biotechnology 27, 767-71 (2009). Thus, there is a need for modified heavy chain constant region sequences that achieve the desired heterodimerization and incorporate modifications that reduce or eliminate effector function, while simultaneously incorporating modifications that reduce or eliminate chain exchange reactions of IgG4. The molecules described herein address these and other challenges.

[0008] Heavy Chain Antibodies In conventional IgG antibodies, the association of the heavy and light chains is due in part to hydrophobic interactions between the light chain constant region and the CH1 constant domain of the heavy chain. There are additional residues in the heavy chain framework 2 (FR2) and framework 4 (FR4) regions that also contribute to this hydrophobic interaction between the heavy and light chains.

[0009] However, it is known that the sera of camelids (suborder Tylopoda, which includes camels, dromedaries, and llamas) contain a major type of antibody consisting only of paired H chains (heavy chain only antibodies or UniAbs™). The UniAbs™ of camelids (Camelus dromedarius, Camelus bactrianus, Lama glama, Lama guanaco, Lama alpaca, and Lama vicugna) have a unique structure consisting of a single variable domain (VHH), a hinge region, and two constant domains (CH2 and CH3) that are highly homologous to the CH2 and CH3 domains of classical antibodies. These UniAbs™ lack the first domain of the constant region (CH1), which is present in the genome but is spliced ​​out during mRNA processing. The absence of the CH1 domain explains the absence of light chains in UniAbs™, since this domain is the anchoring site of the constant domain of the light chain. Such UniAbs™ have naturally evolved with three CDRs derived from conventional antibodies or fragments thereof to confer their antigen-binding specificity and high affinity (Muyldermans, 2001; J Biotechnol 74:277-302; Revets et al., 2005; Expert Opin Biol Ther 5:111-124). Cartilaginous fish such as sharks have also evolved a unique type of immunoglobulin called IgNAR, which lacks light chain polypeptides and is composed entirely of heavy chains. IgNAR molecules can be engineered by molecular engineering to generate variable domains of a single heavy chain polypeptide (vNAR) (Nuttall et al. Eur. J. Biochem. 270, 3543-3554 (2003); Nuttall et al. Function and Bioinformatics 55, 187-197 (2004); Dooley et al., Molecular Immunology 40, 25-33 (2003)).

[0010] The ability of heavy-chain-only antibodies lacking light chains to bind antigens was established in the 1960s (Jaton et al. (1968) Biochemistry, 7, 4185-4195). Heavy-chain immunoglobulins physically separated from light chains retained 80% of the antigen-binding activity compared to tetrameric antibodies. Sitia et al. (1990) Cell, 60, 781-790 showed that heavy-chain-only antibodies lacking light chains could be produced in mammalian cell culture by removing the CH1 domain from a rearranged mouse μ gene. The antibodies produced retained VH binding specificity and had effector function.

[0011] Heavy chain antibodies with high specificity and affinity can be generated against various antigens by immunization (van der Linden, RH, et al. Biochim. Biophys. Acta. 1431, 37-46 (1999)) and VHH moieties can be easily cloned and expressed in yeast (Frenken, LGJ, et al. J. Biotechnol. 78, 11-21 (2000)). Their expression, solubility and stability levels are significantly higher than classical F(ab) or Fv fragments (Ghahroudi, MA et al. FEBS Lett. 414, 521-526 (1997)).

[0012] Mice in which the lambda (lambda) light (L) chain locus and / or the lambda and kappa (kappa) light chain loci are functionally silenced, as well as antibodies produced by such mice, are described in U.S. Patent Nos. 7,541,513 and 8,367,888. Recombinant production of heavy chain-only antibodies in mice and rats has been reported, for example, in WO2006008548, U.S. Patent Publication No. 20100122358, Nguyen et al., 2003, Immunology; 109(1), 93-101, Bruggemann et al., Crit. Rev. Immunol.; 2006, 26(5): 377-90, and Zou et al., 2007, J Exp Med; 204(13): 3271-3283. The generation of knockout rats by embryonic microinjection of zinc finger nucleases is described in Geurts et al., 2009, Science, 325(5939):433. Soluble heavy chain only antibodies and transgenic rodents with heterologous heavy chain loci producing such antibodies are described in U.S. Patent Nos. 8,883,150 and 9,365,655. CAR-T constructs that include single domain antibodies as binding (targeting) domains are described, for example, in Iri-Sofla et al., 2011, Experimental Cell Research 317:2630-2641 and Jamnani et al., 2014, Biochim Biophys Acta, 1840:378-386.

[0013] B cell maturation antigen (BCMA) BCMA, also known as tumor necrosis factor superfamily member 17 (TNFRSF17) (UniProt Q02223), is a cell surface receptor expressed exclusively on plasma cells and plasmablasts. BCMA is the receptor for two ligands of the tumor necrosis factor (TNF) superfamily: APRIL (TNFSF13; proliferation-inducing ligand also known as TALL-2 and TRDL-1; a high-affinity ligand for BCMA) and B-cell activating factor (BAFF) (BLyS; also known as TALL-1; THANK; zTNF4; TNFSF20; and D8Ertd387e; a low-affinity ligand for BCMA). APRIL and BAFF are growth factors that bind to BCMA and promote the survival of plasma cells. BCMA is also highly expressed on malignant plasma cells in human multiple myeloma (MM). Antibodies that bind to BCMA have been described, for example, in Gras et al., 1995, Int. Immunol. 7:1093-1106, WO200124811 and WO200124812. Anti-BCMA antibodies that cross-react with TACI have been described in WO2002 / 066516. Bispecific antibodies against BCMA and CD3 have been described, for example, in US2013 / 0156769 A1 and US2015 / 0376287 A1. Anti-BCMA antibody-MMAE or anti-BCMA antibody-MMAF conjugates have been reported to selectively induce the death of multiple myeloma cells (Tai et al., Blood 2014, 123(20):3128-38). Ali et al., Blood 2016,128(13):1688-700 reported that in a clinical trial (#NCT02215967), chimeric antigen receptor (CAR) T cells targeting BCMA induced remission of multiple myeloma in human patients.

[0014] PSMA PSMA, also known as prostate-specific membrane antigen and glutamic acid carboxypeptidase II (UniProt Q04609), is a type II transmembrane protein with N-acetylated-α-linked acid dipeptidase, folate hydrolase, and dipeptidyl peptidase activity. It is encoded by the human FOLH1 gene and consists of a 19 amino acid cytoplasmic domain, a 24 amino acid transmembrane portion, and a 707 amino acid extracellular portion. The protein is enzymatically active as a non-covalent homodimer. PSMA is expressed in prostate epithelial tissue and upregulated in the neovasculature of prostate cancer and solid tumors. It is also expressed at low levels in healthy tissues such as the brain, kidney, and salivary gland, but its overexpression in malignant prostate tissue makes it an attractive target for therapeutic treatment of prostate cancer. Its high expression in malignant neovasculature may also be suitable for the treatment or imaging of solid tumors. Monoclonal antibodies, antibody-drug conjugates, and chimeric antigen receptor T cells targeting PSMA have been described for the treatment of metastatic prostate cancer (Hernandez-Hoyos et al. 2016, PMID: 27406985; DiPippo et al. 2014, PMID: 25327986; Serganova et al. 2016, PMID: 28345023). In addition, radionuclide conjugates specific for PSMA are being investigated for imaging and treatment of prostate cancer (e.g., Hofman et al., 2018 PMID: 29752180).

[0015] CD19 CD19, also known as B-lymphocyte surface antigen B4 (UniProt P15391), is a cell surface receptor expressed on all human B cells but not on plasma cells. CD19 is a transmembrane protein that recruits cytoplasmic signaling proteins to the membrane and acts within the CD19 / CD21 complex to lower the threshold of the B-cell receptor signaling pathway. CD19 has a relatively large 240 amino acid cytoplasmic tail. The extracellular Ig-like domain is divided into a potential disulfide-linked non-Ig-like domain and an N-linked carbohydrate attachment site. The cytoplasmic tail contains at least nine tyrosine residues near the C-terminus, some of which have been shown to be phosphorylated. The restricted expression of CD19, along with CD20 and CD22, to the B-cell lineage makes it an attractive target for therapeutic treatment of B-cell malignancies. Many monoclonal antibodies and antibody-drug conjugates specific for CD19 have been described (e.g., Naddafi et al. 2015, PMC4644525). Furthermore, anti-CD19 chimeric antigen receptor T cells have been approved for the treatment of leukemia (e.g., Sadelain et al. 2017, PMID:29245005). Summary of the Invention

[0016] Aspects of the invention include an isolated multispecific antibody comprising a first heavy chain polypeptide subunit comprising a mutated human IgG4 constant region comprising the mutations S228P, F234A, L235A, and T366W; and a second heavy chain polypeptide subunit comprising a mutated human IgG4 constant region comprising the mutations S228P, F234A, L235A, T366S, L368A, and Y407V. In some embodiments, the mutated human IgG4 constant region of the first heavy chain polypeptide subunit or the mutated human IgG4 constant region of the second heavy chain polypeptide subunit lacks a CH1 domain. In some embodiments, the mutated human IgG4 constant region of the first heavy chain polypeptide subunit comprises the sequence of SEQ ID NO: 73 or 55, and the mutated human IgG4 constant region of the second heavy chain polypeptide subunit comprises the sequence of SEQ ID NO: 72 or 54.

[0017] In some embodiments, the multispecific antibody according to embodiments of the invention further comprises a first binding moiety having binding specificity for CD3, comprising a heavy chain variable domain comprising a CDR1 sequence comprising the sequence of SEQ ID NO: 36, a CDR2 sequence comprising the sequence of SEQ ID NO: 37, and a CDR3 sequence comprising the sequence of SEQ ID NO: 38; and a light chain variable domain comprising a CDR1 sequence comprising the sequence of SEQ ID NO: 39, a CDR2 sequence comprising the sequence of SEQ ID NO: 40, and a CDR3 sequence comprising the sequence of SEQ ID NO: 41.

[0018] In some embodiments, the CDR1, CDR2 and CDR3 sequences in the heavy chain variable domain of the first binding moiety are in a human VH framework; and the CDR1, CDR2 and CDR3 sequences in the light chain variable domain of the first binding moiety are in a human Vκ framework. In some embodiments, the heavy chain variable domain of the first binding moiety comprises a sequence having at least 95% identity to SEQ ID NO: 42, and the light chain variable domain of the first binding moiety comprises a sequence having at least 95% identity to SEQ ID NO: 43. In some embodiments, the heavy chain variable domain of the first binding moiety comprises the sequence of SEQ ID NO: 42; and the light chain variable domain of the first binding moiety comprises the sequence of SEQ ID NO: 43.

[0019] In some embodiments, a multispecific antibody according to embodiments of the invention further comprises a second binding moiety having binding specificity for a protein other than CD3. In some embodiments, the second binding moiety comprises a single heavy chain variable region in a monovalent or bivalent configuration. In some embodiments, the first binding moiety comprises a light chain polypeptide subunit and a heavy chain polypeptide subunit, and the second binding moiety comprises a heavy chain polypeptide subunit. In some embodiments, the light chain polypeptide subunit of the first binding moiety comprises a light chain constant domain. In some embodiments, the protein other than CD3 is a tumor associated antigen (TAA) or a tumor specific antigen (TSA). In some embodiments, the TAA is B cell maturation antigen (BCMA). In some embodiments, the TAA is CD19. In some embodiments, the TAA is prostate specific membrane antigen (PSMA).

[0020] Aspects of the invention include pharmaceutical compositions comprising the multispecific antibodies described herein, polynucleotides encoding the multispecific antibodies described herein, vectors comprising such polynucleotides, and cells comprising such vectors.

[0021] Aspects of the invention include methods for producing a multispecific antibody as described herein comprising growing a cell as described herein under conditions permissive for expression of the multispecific antibody and isolating the multispecific antibody from the cell.

[0022] Aspects of the invention include methods of treatment comprising administering to an individual in need thereof an effective dose of a multispecific antibody, or a pharmaceutical composition as described herein.

[0023] Aspects of the present invention include the use of a multispecific antibody as described herein in the preparation of a medicament for the treatment of a disease or disorder in an individual in need thereof.

[0024] Aspects of the invention include a method of treating a disease or condition characterized by expression of BCMA comprising administering to an individual in need thereof an effective dose of a multispecific antibody or pharmaceutical composition as described herein. In some embodiments, the disease is an autoimmune disease. In some embodiments, the disease is cancer. In some embodiments, the cancer is myeloma. In some embodiments, the myeloma is multiple myeloma.

[0025] Aspects of the present invention include a method for treating a disease or condition characterized by expression of PSMA, comprising administering to an individual in need thereof an effective dose of a multispecific antibody or pharmaceutical composition as described herein. In some embodiments, the disease is cancer. In some embodiments, the cancer is prostate cancer.

[0026] Aspects of the invention include a method of treating a disease or condition characterized by expression of CD19, comprising administering to an individual in need thereof an effective dose of a multispecific antibody or pharmaceutical composition as described herein. In some embodiments, the disorder is diffuse large B-cell lymphoma (DLBCL). In some embodiments, the disorder is acute lymphoblastic leukemia (ALL). In some embodiments, the disorder is non-Hodgkin's lymphoma (NHL). In some embodiments, the disorder is systemic lupus erythematosus (SLE). In some embodiments, the disorder is rheumatoid arthritis (RA). In some embodiments, the disorder is multiple sclerosis (MS).

[0027] Aspects of the invention include kits for treating a disease or disorder in an individual in need thereof, comprising a multispecific antibody or pharmaceutical composition as described herein, and instructions for use. In some embodiments, the kit further comprises at least one additional reagent. In some embodiments, the at least one additional reagent comprises a chemotherapeutic agent.

[0028] Aspects of the invention include bispecific three-chain antibody-like molecules comprising a first polypeptide subunit comprising a light chain variable domain (VL) comprising the sequence of SEQ ID NO: 43; and a light chain constant domain (CL); a second polypeptide subunit comprising a heavy chain variable domain (VH) comprising the sequence of SEQ ID NO: 42; and a heavy chain constant domain (CH) comprising the sequence of SEQ ID NO: 72 or 73; where the light chain variable domain and the heavy chain variable domain together form a first binding moiety having binding specificity for CD3; and further comprising a heavy chain-only variable region in a mono- or bivalent configuration having binding specificity for a protein other than CD3, and a heavy chain constant domain (CH) comprising the sequence of SEQ ID NO: 54 or 55. In some embodiments, the third polypeptide subunit comprises a heavy chain-only variable region in a bivalent configuration with binding specificity for BCMA.

[0029] An embodiment of the invention includes a bispecific three-chain antibody-like molecule comprising a first polypeptide subunit comprising the sequence of SEQ ID NO:49; a second polypeptide subunit comprising the sequence of SEQ ID NO:56; and a third polypeptide subunit comprising the sequence of SEQ ID NO:58.

[0030] Aspects of the invention include pharmaceutical compositions comprising the bispecific three-chain antibody-like molecules described herein, polynucleotides encoding the bispecific three-chain antibody-like molecules described herein, vectors comprising such polynucleotides, and cells comprising such vectors.

[0031] Aspects of the invention include methods for producing a bispecific three-chain antibody-like molecule as described herein comprising growing a cell as described herein under conditions permissive for expression of the bispecific three-chain antibody-like molecule and isolating the bispecific three-chain antibody-like molecule from the cell.

[0032] Aspects of the invention include methods of treatment comprising administering to an individual in need thereof an effective dose of a bispecific triple-chain antibody-like molecule or a pharmaceutical composition as described herein.

[0033] Aspects of the present invention include the use of a bispecific three-chain antibody-like molecule as described herein in the preparation of a medicament for the treatment of a disease or disorder in an individual in need thereof.

[0034] Aspects of the invention include a method of treating a disease or condition characterized by expression of BCMA, comprising administering to an individual in need thereof an effective dose of a bispecific triple-chain antibody-like molecule or pharmaceutical composition as described herein. In some embodiments, the disease is an autoimmune disease. In some embodiments, the disease is cancer. In some embodiments, the cancer is myeloma. In some embodiments, the myeloma is multiple myeloma.

[0035] Aspects of the invention include kits for treating a disease or disorder in an individual in need thereof, comprising a bispecific triple-chain antibody-like molecule or pharmaceutical composition as described herein, and instructions for use. In some embodiments, the kit further comprises at least one additional reagent. In some embodiments, the at least one additional reagent comprises a chemotherapeutic agent.

[0036] These and further aspects are further described in the remainder of the disclosure, including the Examples. [Brief description of the drawings]

[0037] [Figure 1] Panels AC show diagrams of various multispecific antibodies according to embodiments of the invention. [Diagram 2] Panels A-B show images of non-reducing SDS-PAGE analysis of various antibody species purified by Protein A chromatography. [Diagram 3] Panel A shows an image of a non-reducing SDS-PAGE analysis of various antibody species purified by Protein A chromatography. Panel B shows an image of a reducing SDS-PAGE analysis of the same antibody species as in Panel A. [Figure 4] Panels AD are graphs showing Fcγ receptor-antibody interactions for various IgG1 antibody types, according to embodiments of the invention. [Diagram 5] Panels A-E are graphs showing Fcγ receptor-antibody interactions for various IgG4 antibody types, according to embodiments of the invention. [Figure 6] Panels AD are graphs showing Fcγ receptor-antibody interactions for various IgG1 antibody types, according to embodiments of the invention. [Figure 7] Panels A-E are graphs showing Fcγ receptor-antibody interactions for various IgG4 antibody types, according to embodiments of the invention. [Figure 8] Panel A is a graph showing cell binding to human PSMA, and Panel B is a graph showing cell binding to cynomolgus PSMA. [Figure 9] 1 is a graph showing T cell-mediated lysis of PSMA-positive cells using unstimulated T cells. [Figure 10] 1 is a graph showing T cell-mediated lysis of PSMA-positive cells using pre-activated T cells. [Figure 11] FIG. 1 is a graph showing percent specific lysis of PSMA-negative DU145 cells as a function of multispecific antibody concentration in the presence of pre-activated T cells. [Figure 12] 1 is a graph showing binding of PSMAxCD3 bispecific antibodies to PSMA positive and negative cells. [Figure 13] 1 is a graph showing T cell-mediated lysis of PSMA positive cells. [Figure 14] Panel A is a graph showing T cell-mediated lysis of PSMA-positive cells as a function of antibody concentration. Panel B is a graph showing cytokine (IFNγ) release as a function of antibody concentration. Panel C is a graph showing cytokine (IL-2) release as a function of antibody concentration. [Figure 15] Panel A is a graph showing T cell proliferation as a function of antibody concentration. Panel B is a graph showing T cell proliferation as a function of antibody concentration. Panel C is a graph showing the CD8 to CD4 ratio of expanded T cells. Panel D is a graph showing the CD8 to CD4 ratio of expanded T cells. [Figure 16] 1 is a graph showing inhibition of 22Rv1 tumor growth in a tumor xenograft model. [Figure 17] FIG. 1 is a graph showing % CD4+CD69+ T cells as a function of bispecific antibody concentration for the bispecific antibodies indicated in the legend. [Figure 18] FIG. 1 is a graph showing % CD8+CD69+ T cells as a function of bispecific antibody concentration for the bispecific antibodies indicated in the legend. [Figure 19] FIG. 1 is a graph showing % CD8+CD69+ T cells as a function of bispecific antibody concentration for the bispecific antibodies indicated in the legend. [Figure 20]FIG. 1 is a graph showing % CD8+CD69+ T cells as a function of bispecific antibody concentration for the bispecific antibodies indicated in the legend. [Figure 21] Panels A-D show several graphs illustrating bispecific antibody-mediated tumor cell lysis. Anti-CD3 x anti-BCMA bispecific antibodies were assayed for their ability to kill three different BCMA+ tumor cells and one BCMA-negative cell line through redirection of activated primary T cells. In this experiment, tumor cells were mixed with activated pan T cells at an E:T ratio of 10:1 along with the addition of bispecific antibodies. Panel A shows the killing of RPMI-8226 cells, Panel B shows the killing of NCI-H929 cells, Panel C shows the killing of U-266 cells, and Panel D shows the killing of negative control K562 cells. The x-axis shows the concentration of antibody used and the y-axis shows the lysis (%) of tumor cells 6 hours after addition of antibody. [Figure 22] Panels A-D show several graphs illustrating bispecific antibody-mediated IL-2 release. Resting human T cells were cultured with various tumor cell lines and increasing doses of anti-CD3 x anti-BCMA bispecific antibodies, and the levels of IL-2 cytokine release were measured. Panel A shows IL-2 release stimulated by RPMI-8226 cells, Panel B shows IL-2 release stimulated by NCI-H929 cells, Panel C shows IL-2 release stimulated by U-266 cells, and Panel D shows IL-2 release stimulated by negative control K562 cells. [Diagram 23] Panels A-D show several graphs illustrating bispecific antibody-mediated IFN-γ release. Resting human T cells were cultured with various tumor cell lines and increasing doses of anti-CD3 x anti-BCMA bispecific antibodies, and the levels of IFN-γ cytokine release were measured. Panel A shows IFN-γ release stimulated by RPMI-8226 cells, Panel B shows IFN-γ release stimulated by NCI-H929 cells, Panel C shows IFN-γ release stimulated by U-266 cells, and Panel D shows IFN-γ release stimulated by negative control K562 cells. [Figure 24]1 is an image of a non-reducing SDS-PAGE analysis of various antibody species purified by Protein A chromatography. [Diagram 25] 1 is a table showing the % HMW, % monomer, and % LMW species from samples of the indicated constructs after purification. [Figure 26] Panels AD are graphs showing Fcγ receptor-antibody interactions for various IgG4 antibody types, according to embodiments of the invention. [Figure 27] Panels A and B are graphs showing the percentage of CD4+CD69+ T cells (Panel A) and the percentage of CD8+CD69+ T cells (Panel B) as a function of bispecific antibody concentration for CD3xBCMA bispecific antibodies as indicated in the legend. [Figure 28] Panels A and B are graphs showing the percentage of CD4+CD69+ T cells (Panel A) and the percentage of CD8+CD69+ T cells (Panel B) as a function of bispecific antibody concentration for CD3xBCMA bispecific antibodies as indicated in the legend. [Figure 29] Panels A and B are graphs showing the percentage of CD4+CD69+ T cells (Panel A) and the percentage of CD8+CD69+ T cells (Panel B) as a function of bispecific antibody concentration for CD3xBCMA bispecific antibodies as indicated in the legend. [Diagram 30] Panels A and B are graphs showing the percentage of CD4+CD69+ T cells (Panel A) and the percentage of CD8+CD69+ T cells (Panel B) as a function of bispecific antibody concentration for the CD3×PSMA bispecific antibody indicated in the legend. [Diagram 31] Panels A and B are graphs showing the percentage of CD4+CD69+ T cells (Panel A) and the percentage of CD8+CD69+ T cells (Panel B) as a function of bispecific antibody concentration for the CD3×PSMA bispecific antibody indicated in the legend. [Diagram 32]Panels A and B are graphs showing the percentage of CD4+CD69+ T cells (Panel A) and the percentage of CD8+CD69+ T cells (Panel B) as a function of bispecific antibody concentration for the CD3×PSMA bispecific antibody indicated in the legend. [Diagram 33] Panels A and B are graphs showing the percentage of CD4+CD69+ T cells (Panel A) and the percentage of CD8+CD69+ T cells (Panel B) as a function of bispecific antibody concentration for the CD3xCD19 bispecific antibodies indicated in the legend. [Diagram 34] Panels A and B are graphs showing the percentage of CD4+CD69+ T cells (Panel A) and the percentage of CD8+CD69+ T cells (Panel B) as a function of bispecific antibody concentration for the CD3xCD19 bispecific antibodies indicated in the legend. [Diagram 35] Panels A and B are graphs showing the percentage of CD4+CD69+ T cells (Panel A) and the percentage of CD8+CD69+ T cells (Panel B) as a function of bispecific antibody concentration for the CD3xCD19 bispecific antibodies indicated in the legend. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0038] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are described in “Molecular Cloning: A Laboratory Manual”, second edition (Sambrook et al., 1989); Biology” (FMAusubel et al., eds., 1987, and periodic updates), “PCR: The Polymerase Chain Reaction”, (Mullis et al., ed., 1994), “A Practical Guide to Molecular Cloning” (Perbal Bernard V., 1988), “Phage Display: A Laboratory Manual” (Barbas et al., 2001), Harlow, Lane and Harlow, Using Antibodies:A Laboratory Manual:Portable Protocol No.I,Cold Spring Harbor Laboratory (1998), and Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory; (1988).

[0039] Where a range of values ​​is provided, it is understood that each intervening value between the upper and lower limits of that range, to one-tenth of the unit of the lower limit, as well as any other stated or intervening value in that stated range, is encompassed within the invention, unless the context clearly dictates otherwise. The upper and lower limits of these smaller ranges may be independently included in the smaller ranges, and are also encompassed herein, subject to any specific excluded limits in the stated range. Where a stated range includes one or both of its upper and lower limits, ranges excluding either or both of those included upper and lower limits are also encompassed within the invention.

[0040] Unless otherwise specified, antibody residues herein are numbered according to the Kabat numbering system (e.g., Kabat et al., Sequences of Immunological Interest. 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)).

[0041] In the following description, numerous specific details are set forth to provide a more thorough understanding of the present invention. However, it will be apparent to one of ordinary skill in the art that the present invention may be practiced without one or more of these specific details. In other instances, well-known features and procedures well known to those skilled in the art have not been described in order to avoid obscuring the present invention.

[0042] All references cited throughout this disclosure, including patent applications and publications, are hereby incorporated by reference in their entirety.

[0043] I. Definition "Comprising" means that the recited element is necessary for the composition / method / kit, but other elements may be included to form the composition / method / kit, etc., within the scope of the claim.

[0044] "Consisting essentially of" means limiting the scope of the described composition or method to certain materials or steps that do not materially affect the basic and novel characteristic(s) of the invention.

[0045] "Consisting of" means that any element, step, or ingredient not specified in the claim is excluded from the composition, method, or kit.

[0046] Antibody residues herein are numbered according to the Kabat numbering system and the EU numbering system. The Kabat numbering system is generally used when referring to residues in the variable domain (approximately residues 1-113 of the heavy chain) (e.g., Kabat et al., Sequences of Immunological Interest. 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). The "EU numbering system" or "EU index" is generally used when referring to residues in the immunoglobulin heavy chain constant region (e.g., the EU index reported in Kabat et al., supra). The "EU index as described in Kabat" refers to the residue numbering of the human IgG1 EU antibody. Unless otherwise stated herein, references to residue numbers in the variable domain of an antibody refer to residue numbering according to the Kabat numbering system. Unless otherwise stated herein, references to residue numbers in the constant domain of an antibody refer to residue numbering according to the EU numbering system.

[0047] An "antibody" or "immunoglobulin" refers to a molecule comprising at least one heavy chain and one light chain, where the amino-terminal domains of the heavy and light chains are variable in sequence and are therefore commonly referred to as variable region domains or variable heavy (VH) or variable light (VL) domains. The two domains traditionally associate to form a specific binding region, although, as discussed herein, specific binding can also be obtained with variable sequence of the heavy chain alone, and various non-natural configurations of antibodies are known and used in the art.

[0048] A "functional" or "biologically active" antibody or antigen-binding molecule (including heavy-chain-only antibodies and multispecific (e.g., bispecific) three-chain antibody-like molecules (TCAs described herein)) is a molecule that can exert one or more of its natural activities in structural, regulatory, biochemical or biophysical events. For example, a functional antibody or other binding molecule, e.g., a TCA, can have the ability to specifically bind to an antigen, which binding can then trigger or alter a cellular or molecular event, such as a signal transduction or enzymatic activity. A functional antibody or other binding molecule, e.g., a TCA, can also block ligand activation of a receptor or act as an agonist or antagonist. The ability of an antibody or other binding molecule, e.g., a TCA, to exert one or more of its natural activities depends on several factors, including the proper folding and assembly of the polypeptide chain.

[0049] The term antibody may refer to a full-length heavy chain, a full-length light chain, an intact immunoglobulin molecule, or an immunologically active portion of any of these polypeptides, i.e., a polypeptide that contains an antigen-binding site that immunospecifically binds to an antigen of a target of interest or a portion thereof, including, but not limited to, cancer cells or cells that produce autoimmune antibodies associated with autoimmune diseases. The immunoglobulins disclosed herein may be of any type (e.g., IgG, IgE, IgM, IgD, and IgA), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass (including subclasses engineered with modified Fc portions that attenuate or enhance effector cell activity) of immunoglobulin molecule. The light chain of the subject antibody may be a kappa light chain (Vkappa) or a lambda light chain (Vlambda). The immunoglobulin may be derived from any species. In one aspect, the immunoglobulin is primarily of human origin.

[0050] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies constituting the population are identical except for possible naturally occurring mutations that may exist in small amounts. Monoclonal antibodies are directed against a single antigenic site and are highly specific. Furthermore, in contrast to conventional (polyclonal) antibody preparations that contain different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. Monoclonal antibodies according to the present invention can be produced by the hybridoma method first described by Kohler et al. (1975) Nature 256:495, or can be produced, for example, through recombinant protein production methods (see, for example, U.S. Patent No. 4,816,567).

[0051] The term "variable" as used in reference to antibodies refers to the fact that the sequences of certain portions of antibody variable domains vary widely among antibodies and that these sequences are used in the binding and specificity of each particular antibody to its particular antigen. However, variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called hypervariable regions in both the light and heavy chain variable domains. The more highly conserved portions of the variable domains are called framework regions (FRs). Naturally occurring heavy and light chain variable domains each contain four FRs, which adopt a predominantly β-sheet configuration and are connected by three hypervariable regions that form loops that connect, and in some cases form part of, the β-sheet structure. The hypervariable regions in each chain are held in close proximity to the hypervariable regions of the other chain by the FRs and contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participating in antibody-dependent cellular cytotoxicity (ADCC).

[0052] As used herein, the term "hypervariable region" refers to the amino acid residues of an antibody that are responsible for antigen binding. The hypervariable region generally comprises amino acid residues from the "complementarity determining region" or "CDR" (e.g., residues 31-35 (H1), 50-65 (H2), and 95-102 (H3) of the heavy chain variable domain, Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and / or residues from the "hypervariable loop" residues 26-32 (H1), 53-55 (H2), and 96-101 (H3) of the heavy chain variable domain, Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)). In some embodiments, "CDR" refers to the complementarity determining regions of an antibody as defined in Lefranc, MP et al., IMGT, the international ImMunoGeneTics database, Nucleic Acids Res., 27:209-212 (1999). "Framework Region" or "FR" residues are those variable domain residues other than the hypervariable region / CDR residues as defined herein.

[0053] Exemplary CDR designations are provided herein, however, one of skill in the art will appreciate that several definitions of CDRs are commonly used, including the Kabat definition, which is based on sequence variability and is the most commonly used (see, "Zhao et al. A germline knowledge based computational approach for determining antibody complementarity determining regions." Mol Immunol. 2010;47:694-700). The Chothia definition is based on the location of structural loop regions (Chothia et al. "Conformations of immunoglobulin hypervariable regions." Nature. 1989;342:877-883).Alternative CDR definitions of interest include, but are not limited to, those described in Honegger, "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool." J Mol Biol. 2001; 309: 657-670; Ofran et al. "Automated identification of complementarity determining regions (CDRs) reveals peculiar characteristics of CDRs and B-cell epitopes." J Immunol. 2008; 181: 6230-6235; Almagro "Identification of differences in the specificity-determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires." J Mol Recognit. 2004; 17: 132-143; and Padlan et al. "Identification of specificity-determining residues in antibodies." Faseb J. 1995;9:133-139, each of which is specifically incorporated herein by reference.

[0054] The terms "heavy chain-only antibody" and "heavy chain antibody" are used interchangeably herein and refer in the broadest sense to an antibody or one or more portions of an antibody, e.g., one or more arms of an antibody lacking the light chain of a conventional antibody. These terms specifically include, but are not limited to, homodimeric antibodies comprising a VH antigen-binding domain and CH2 and CH3 constant domains but lacking a CH1 domain, functional (antigen-binding) variants of such antibodies, soluble VH variants, Ig-NARs and functional fragments thereof comprising a homodimer of one variable domain (V-NAR) and five C-like constant domains (C-NARs), and soluble single domain antibodies (sUniDabs™). In one embodiment, a heavy chain-only antibody comprises a variable region antigen-binding domain consisting of framework 1, CDR1, framework 2, CDR2, framework 3, CDR3, and framework 4. In another embodiment, a heavy chain-only antibody comprises an antigen-binding domain, at least a portion of the hinge region, and the CH2 and CH3 domains. In another embodiment, the heavy chain-only antibody consists of an antigen-binding domain, at least a portion of the hinge region, and a CH2 domain. In a further embodiment, the heavy chain-only antibody consists of an antigen-binding domain, at least a portion of the hinge region, and a CH3 domain. Heavy chain-only antibodies in which the CH2 and / or CH3 domains are truncated are also included herein. In a further embodiment, the heavy chain consists of an antigen-binding domain and at least one CH (CH1, CH2, CH3, or CH4) domain, but does not include the hinge region. Heavy chain-only antibodies may be in the form of a dimer in which two heavy chains are disulfide-linked or otherwise covalently or non-covalently bound to each other. Heavy chain-only antibodies may belong to the IgG subclass, although antibodies belonging to other subclasses such as IgM, IgA, IgD, and IgE subclasses are also included herein. In a particular embodiment, the heavy chain antibody is of the IgG1, IgG2, IgG3, or IgG4 subtype, in particular the IgG1 subtype. In one embodiment, the heavy chain-only antibodies herein are used as the binding (targeting) domain of a chimeric antigen receptor (CAR).This definition specifically includes human heavy chain only antibodies produced by human immunoglobulin transgenic rats (UniRat™), called UniAbs™. The variable regions (VH) of UniAbs™, also called UniDabs™, are variable building blocks that can be bound to Fc regions or serum albumin to develop novel therapeutics with multispecificity, increased potency and extended half-life. Homodimeric UniAbs™ are devoid of light chains and therefore lack a VL domain, so that the antigen is recognized by a single domain, namely the variable domain of the heavy chain of the heavy chain antibody (VH or VHH).

[0055] As used herein, an "intact antibody chain" is an antibody chain that comprises a full-length variable region and a full-length constant region (Fc). An intact "conventional" antibody comprises an intact light chain and an intact heavy chain, as well as the light chain constant domain (CL) and heavy chain constant domains, CH1, hinge, CH2 and CH3, for secreted IgG. Other isotypes, such as IgM or IgA, may have different CH domains. The constant domains may be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variants thereof. An intact antibody may have one or more "effector functions", which refers to the biological activities attributable to the Fc constant region of an antibody (native sequence Fc region or amino acid sequence variant Fc region). Examples of antibody effector functions include C1q binding, complement-dependent cytotoxicity, Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, and down-regulation of cell surface receptors. Constant region variants include variants that alter effector properties, binding to Fc receptors, and the like.

[0056] Depending on the amino acid sequence of the Fc (constant domain) of the heavy chain, antibodies and various antigen-binding proteins can be provided as different classes. There are five major classes of heavy chain Fc regions: IgA, IgD, IgE, IgG, and IgM, some of which can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The Fc constant domains corresponding to the different classes of antibodies can be called α, δ, ε, γ, and μ, respectively. The subunit structures and three-dimensional configurations of the different classes of immunoglobulins are well known. Forms of Ig include hinge-modified or hingeless forms (Roux et al (1998) J. Immunol. 161:4083-4090; Lund et al (2000) Eur. J. Biochem. 267:7246-7256; US2005 / 0048572; US2004 / 0229310). The light chains of antibodies from any vertebrate species can be assigned to one of two types, called κ (kappa) and λ (lambda), based on the amino acid sequences of their constant domains. Antibodies according to embodiments of the invention can comprise a κ light chain sequence or a λ light chain sequence.

[0057] A "functional Fc region" possesses the "effector functions" of a native sequence Fc region. Non-limiting examples of effector functions include C1q binding, CDC, Fc receptor binding, ADCC, ADCP, downregulation of cell surface receptors (e.g., B cell receptors), and the like. Such effector functions generally require the Fc region to interact with a receptor, e.g., FcγRI, FCγRIIA, FcγRIIB1, FCγRIIB2, FCγRIIIA, FCγRIIIB receptors, and low affinity FcRn receptors, and can be assessed using a variety of assays known in the art. A "dead" or "silenced" Fc is an Fc that has been mutated to retain activity, e.g., with respect to extended serum half-life, but does not activate high affinity Fc receptors or has reduced affinity for Fc receptors.

[0058] A "native sequence Fc region" comprises an amino acid sequence identical to the amino acid sequence of an Fc region found in nature. Native sequence human Fc regions include, for example, native sequence human IgG1 Fc region (non-A and A allotypes), native sequence human IgG2 Fc region, native sequence human IgG3 Fc region, and native sequence human IgG4 Fc region, as well as naturally occurring variants thereof.

[0059] A "variant Fc region" comprises an amino acid sequence that differs from the amino acid sequence of a native sequence Fc region by at least one amino acid modification, preferably one or more amino acid substitution(s). Preferably, the variant Fc region has at least one amino acid substitution compared to a native sequence Fc region or the Fc region of a parent polypeptide, e.g., about 1 to about 10 amino acid substitutions, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions, and preferably about 1 to about 5 amino acid substitutions, in the native sequence Fc region or in the Fc region of the parent polypeptide. A variant Fc region herein preferably retains at least about 80% homology with the native sequence Fc region and / or the Fc region of the parent polypeptide, and most preferably at least about 90% homology therewith, more preferably at least about 95% homology therewith.

[0060] The human IgG4 Fc amino acid sequence (UniProtKB No. P01861) is set forth herein as SEQ ID NO: 45. Silenced IgG1 is described, for example, in Boesch, AW, et al., "Highly parallel characterization of IgG Fc binding interactions." MAbs, 2014.6(4):p.915-27, the disclosure of which is incorporated herein by reference in its entirety.

[0061] Other Fc variants are possible, including, but not limited to, variants that lack regions capable of forming disulfide bonds, or variants that remove specific amino acid residues at the N-terminus of native Fc, or variants that add methionine residues.Thus, in some embodiments, one or more Fc portions of an antibody may contain one or more mutations in the hinge region to eliminate disulfide bonds.In yet another embodiment, the hinge region of the Fc may be completely removed.In yet another embodiment, an antibody may contain an Fc variant.

[0062] Furthermore, Fc variants can be constructed to eliminate or substantially reduce effector functions by substituting (mutating), deleting, or adding amino acid residues to effect complement binding or Fc receptor binding. For example, but not limited to, deletions may be made in complement binding sites, such as the C1q binding site. Techniques for preparing such sequence derivatives of immunoglobulin Fc fragments are disclosed in International Patent Publications WO97 / 34631 and WO96 / 32478. Furthermore, the Fc domain can be modified by phosphorylation, sulfation, acylation, glycosylation, methylation, farnesylation, acetylation, amidation, and the like.

[0063] In some embodiments, the antibody comprises a variant human IgG4 CH3 domain sequence comprising a T366W mutation, which may optionally be referred to herein as an IgG4 CH3 knob sequence. In some embodiments, the antibody comprises a variant human IgG4 CH3 domain sequence comprising a T366S mutation, a L368A mutation, and a Y407V mutation, which may optionally be referred to herein as an IgG4 CH3 hole sequence. The IgG4 CH3 mutations described herein can be utilized in any suitable manner to place a "knob" in the first heavy chain constant region of a first monomer of an antibody dimer and a "hole" in the second heavy chain constant region of a second monomer of the antibody dimer, thereby facilitating proper pairing (heterodimerization) of the desired pair of heavy chain polypeptide subunits in the antibody.

[0064] In some embodiments, the antibody comprises a heavy chain polypeptide subunit comprising a variant human IgG4 Fc region comprising an S228P, F234A, L235A, and T366W mutation (knob).In some embodiments, the antibody comprises a heavy chain polypeptide subunit comprising a variant human IgG4 Fc region comprising an S228P, F234A, L235A, and T366S, L368A, and Y407V mutation (hole).

[0065] The term "antibody comprising an Fc region" refers to an antibody that comprises an Fc region. The C-terminal lysine (residue 447 according to the EU numbering system) of the Fc region may be removed, for example, during purification of the antibody or by recombinant engineering of the nucleic acid encoding the antibody. Thus, an antibody having an Fc region according to the present invention may include an antibody that does or does not contain K447.

[0066] An embodiment of the present invention includes an antibody comprising a heavy chain-only variable region in a monovalent or bivalent configuration. As used herein, the term "monovalent configuration" as used in reference to a heavy chain-only variable region domain means that there is only one heavy chain-only variable region domain with a single binding site (see FIG. 1, panel A, right arm of the antibody). In contrast, the term "bivalent configuration" as used in reference to a heavy chain-only variable region domain means that there are two heavy chain-only variable region domains (each with a single binding site) and connected by a linker sequence (see FIG. 1, panels B and C, right arm of the antibody). Non-limiting examples of linker sequences are discussed further herein, including, but not limited to, GS linker sequences of various lengths. When the heavy chain-only variable region is in a bivalent configuration, each of the two heavy chain-only variable region domains has binding affinity for the same antigen or different antigens (e.g., for different epitopes on the same protein, for two different proteins, etc.). However, unless otherwise specified, a heavy chain-only variable region designated as being in a "bivalent configuration" is understood to comprise two identical heavy chain-only variable region domains connected by a linker sequence, where each of the two identical heavy chain-only variable region domains has binding affinity for the same target antigen.

[0067] Aspects of the invention include antibodies with multispecific configurations, including but not limited to bispecific, trispecific, etc. A wide variety of methods and protein configurations for bispecific monoclonal antibodies (BsMAB), trispecific antibodies, etc. are known and in use.

[0068] Various methods for producing multivalent artificial antibodies have been developed by recombinantly fusing the variable domains of two or more antibodies. In some embodiments, the first and second antigen-binding domains on a polypeptide are connected by a polypeptide linker. One non-limiting example of such a polypeptide linker is the GS linker, which has an amino acid sequence of four glycine residues followed by one serine residue, which is repeated n times in the GS linker, where n is an integer ranging from 1 to about 10, e.g., 2, 3, 4, 5, 6, 7, 8, or 9. Non-limiting examples of such linkers include GGGGS (SEQ ID NO: 70) (n=1) and GGGGSGGGGS (SEQ ID NO: 71 (n=2). Other suitable linkers can also be used, e.g., as described in Chen et al., Adv Drug Deliv Rev. 2013 October 15;65(10):1357-69, the disclosure of which is incorporated herein by reference in its entirety.

[0069] The term "tri-chain antibody-like molecule" or "TCA" is used herein to refer to an antibody-like molecule that comprises, consists essentially of, or consists of three polypeptide subunits, two of which comprise, consist essentially of, or consist of one heavy and one light chain of a monoclonal antibody, or a functional antigen-binding fragment of such antibody chains, comprising an antigen-binding region and at least one CH domain. This heavy / light chain pair has binding specificity for a first antigen. The third polypeptide subunit comprises, consists essentially of, or consists of a heavy chain-only antibody that does not contain a CH1 domain, an Fc portion that comprises a CH2 and / or CH3 and / or CH4 domain, and one or more antigen-binding domains (e.g., two antigen-binding domains) that bind to an epitope of a second antigen or a different epitope of a first antigen, such binding domains being derived from or having sequence identity to the variable regions of the heavy or light chains of the antibody. Such variable region portions are V H and / or V L Gene segments, D and J HGene segment, or J L The variable region can be encoded by a rearranged V H DJ H , V L DJ H , V H J L , or V L J L It can be encoded by a gene segment.

[0070] The TCA binding compounds utilize "heavy chain only antibodies" or "heavy chain antibodies" or "heavy chain polypeptides", which as used herein means single chain antibodies comprising the heavy chain constant regions CH2 and / or CH3 and / or CH4, but not the CH1 domain. In one embodiment, the heavy chain antibody consists of an antigen binding domain, at least a portion of a hinge region, and a CH2 and CH3 domain. In another embodiment, the heavy chain antibody consists of an antigen binding domain, at least a portion of a hinge region, and a CH2 domain. In a further embodiment, the heavy chain antibody consists of an antigen binding domain, at least a portion of a hinge region, and a CH3 domain. Heavy chain antibodies in which the CH2 and / or CH3 domains are truncated are also included herein. In a further embodiment, the heavy chain consists of an antigen binding domain and at least one CH (CH1, CH2, CH3, or CH4) domain, but not the hinge region. Heavy chain-only antibodies may be in the form of a dimer in which two heavy chains are disulfide-bonded or covalently or non-covalently bound to each other, and may optionally include an asymmetric interface between one or more CH domains to facilitate proper pairing between the polypeptide chains. Heavy chain antibodies may belong to the IgG subclass, but antibodies belonging to other subclasses, such as IgM, IgA, IgD and IgE subclasses, are also included herein. In certain embodiments, the heavy chain antibodies are of IgG1, IgG2, IgG3 or IgG4 subtypes, particularly IgG1 or IgG4 subtypes. Non-limiting examples of TCA binding compounds are described, for example, in WO2017 / 223111 and WO2018 / 052503, the disclosures of which are incorporated herein by reference in their entirety.

[0071] Heavy chain antibodies constitute about one quarter of the IgG antibodies produced by camelids, such as camels and llamas (Hamers-Casterman C., et al. Nature. 363, 446-448 (1993)). These antibodies are formed by two heavy chains but have no light chains. As a result, the variable antigen-binding portion is called a VHH domain, which represents the smallest naturally occurring intact antigen-binding site, only about 120 amino acids in length (Desmyter, A., et al. J. Biol. Chem. 276, 26285-26290 (2001)). Heavy chain antibodies with high specificity and affinity can be generated against a variety of antigens by immunization (van der Linden, RH, et al. Biochim. Biophys. Acta. 1431, 37-46 (1999)) and VHH moieties can be easily cloned and expressed in yeast (Frenken, LGJ, et al. J. Biotechnol. 78, 11-21 (2000)). Their expression, solubility and stability levels are significantly higher than classical F(ab) or Fv fragments (Ghahroudi, MA et al. FEBS Lett. 414, 521-526 (1997)). Sharks have also been shown to have a single VH-like domain in their antibodies, called VNAR. (Nuttall et al.Eur.J.Biochem.270,3543-3554(2003), Nuttall et al. Function and Bioinformatics 55,187-197(2004), Dooley et al.,Molecular Immunology 40,25-33(2003)).

[0072] The term "CD3" refers to the human CD3 protein multisubunit complex. The CD3 protein multisubunit complex is composed of six distinct polypeptide chains. These include the CD3 gamma chain (SwissProt P09693), the CD3 delta chain (SwissProt P04234), two CD3 epsilon chains (SwissProt P07766), and one CD3 zeta chain homodimer (SwissProt 20963), which is associated with the T cell receptor alpha and beta chains. The term "CD3" includes any CD3 variants, isoforms, and species homologs that can be expressed naturally by cells (including T cells) or on cells transfected with genes or cDNAs encoding those polypeptides, unless otherwise specified.

[0073] A "BCMAxCD3 antibody" is a multispecific heavy chain only antibody, e.g., a bispecific heavy chain only antibody, that contains two different antigen binding regions, one of which specifically binds to the antigen BCMA and one of which specifically binds to CD3. A "PSMAxCD3 antibody" is a multispecific heavy chain only antibody, e.g., a bispecific heavy chain only antibody, that contains two different antigen binding regions, one of which specifically binds to the antigen PSMA and one of which specifically binds to CD3. A "CD19xCD3 antibody" is a multispecific heavy chain only antibody, e.g., a bispecific heavy chain only antibody, that contains two different antigen binding regions, one of which specifically binds to the antigen CD19 and one of which specifically binds to CD3.

[0074] The term "BCMA" as used herein relates to human B-cell maturation antigen, also known as BCMA, CD269, and TNFRSF17 (UniProt Q02223), which is a member of the tumor necrosis receptor superfamily that is preferentially expressed in differentiated plasma cells. The extracellular domain of human BCMA consists of amino acids 1-54 (or 5-51) according to UniProt.

[0075] The terms "anti-BCMA heavy chain only antibody" and "BCMA heavy chain only antibody" are used herein to refer to a heavy chain only antibody as defined above that immunospecifically binds to BCMA.

[0076] As used herein, the term "PSMA" refers to a type II transmembrane protein with N-acetylated-α-linked acid depeptidase, folate hydrolase and dipeptidyl peptidase activity. The term "PSMA" includes PSMA proteins of any human and non-human animal species, and specifically includes human PSMA as well as PSMA of non-human mammals.

[0077] As used herein, the term "human PSMA" includes any variant, isoform, and species homologue of human PSMA (UniProt Q04609), regardless of its source or mode of preparation. Thus, "human PSMA" includes human PSMA naturally expressed by cells and PSMA expressed on cells transfected with the human PSMA gene.

[0078] As defined above, the terms "anti-PSMA heavy chain only antibody," "PSMA heavy chain only antibody," "anti-PSMA heavy chain antibody," and "PSMA heavy chain antibody" are used interchangeably herein to refer to heavy chain only antibodies that immunospecifically bind to PSMA, including human PSMA, as defined above. This definition includes, but is not limited to, human heavy chain antibodies produced by transgenic animals, such as transgenic rats or mice expressing human immunoglobulins, including UniRats™ that produce human anti-PSMA UniAb™ antibodies, as defined above.

[0079] As used herein, the terms "CD19" and "cluster of differentiation 19" refer to a molecule expressed at all stages of B cell development up to terminal differentiation into plasma cells. The term "CD19" includes the CD19 protein of any human and non-human animal species, and specifically includes human CD19 and non-human mammalian CD19.

[0080] As used herein, the term "human CD19" includes any variant, isoform, and species homologue of human CD19 (UniProt P15391), regardless of its source or mode of preparation. Thus, "human CD19" includes human CD19 naturally expressed by cells, and CD19 expressed on cells transfected with the human CD19 gene.

[0081] The terms "anti-CD19 heavy chain only antibody", "CD19 heavy chain only antibody", "anti-CD19 heavy chain antibody" and "CD19 heavy chain antibody" are used interchangeably herein and refer to heavy chain only antibodies as defined above that immunospecifically bind to CD19, including human CD19 as defined above. This definition includes human heavy chain antibodies produced by transgenic animals, such as transgenic rats or mice expressing human immunoglobulins, including, but not limited to, UniRats™ producing human anti-CD19 UniAb™ antibodies as defined above.

[0082] "Amino acid sequence identity percentage" to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence after aligning the sequences and introducing gaps as necessary to achieve the maximum sequence identity percentage (any conservative substitutions are not considered as part of sequence identity). Alignment for the purpose of determining amino acid sequence identity percentage can be achieved in various ways that are within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine the appropriate parameters for aligning sequences, including any algorithm required to obtain maximum alignment over the entire length of the sequences being compared. However, for the purposes herein, the sequence comparison computer program ALIGN-2 is used to generate amino acid sequence identity values ​​(%).

[0083] An "isolated" antibody is one that has been identified and separated and / or recovered from a component of its natural environment. Contaminating components of its natural environment are substances that would interfere with diagnostic or therapeutic uses of the antibody, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In a preferred embodiment, the antibody is purified to (1) greater than 95% by weight, most preferably greater than 99% by weight, of the antibody as determined by the Lowry method, (2) sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence using a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or non-reducing conditions with Coomassie blue, or preferably silver stain. Isolated antibodies include antibodies in situ in recombinant cells, since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibodies will be prepared by at least one purification step.

[0084] The antibodies of the present invention include multispecific antibodies. Multispecific antibodies have multiple binding specificities. The term "multispecific" specifically includes "bispecific" and "trispecific", as well as higher order independent specific binding affinities such as higher order polyepitopic specificity, as well as tetravalent antibodies and antibody fragments. The terms "multispecific antibody", "multispecific heavy chain only antibody", "multispecific heavy chain antibody", and "multispecific UniAb™" are used in the broadest sense herein to encompass all antibodies with multiple binding specificities.

[0085] Multispecific antibodies of the invention specifically include antibodies that immunospecifically bind to two or more non-overlapping epitopes on a BCMA protein, a PSMA protein, or a CD19 protein, such as a human BCMA protein, a human PSMA protein, or a human CD19 protein (i.e., bivalent and biparatopic). Multispecific heavy chain antibodies of the invention also specifically include antibodies that immunospecifically bind to an epitope on a BCMA protein, a PSMA protein, or a CD19 protein, such as a human BCMA protein, a human PSMA protein, or a human CD19 protein, and an epitope on a different protein, such as a CD3 protein, e.g., human CD3 (i.e., bivalent and biparatopic). Multispecific heavy chain antibodies of the invention also specifically include antibodies that immunospecifically bind to two or more non-overlapping or partially overlapping epitopes on a BCMA protein, a PSMA protein, or a CD19 protein, such as a human BCMA protein, a human PSMA protein, or a human CD19 protein, and an epitope on a different protein, such as a CD3 protein, e.g., human CD3 protein (i.e., bivalent and biparatopic).

[0086] An "epitope" is a site on the surface of an antigen molecule to which a single antibody molecule binds. Typically, an antigen has several or many different epitopes and reacts with many different antibodies. The term specifically includes linear and conformational epitopes.

[0087] "Epitope mapping" is the process of identifying the binding site or epitope of an antibody on a target antigen. Antibody epitopes can be linear or conformational epitopes. Linear epitopes are formed by a contiguous sequence of amino acids in a protein. Conformational epitopes are formed by amino acids that are discontinuous in the protein sequence but come together when the protein folds into its three-dimensional structure.

[0088] "Polyepitopic specificity" refers to the ability to specifically bind to two or more different epitopes on the same or different target(s). As mentioned above, the present invention specifically includes heavy chain antibodies with polyepitopic specificity, i.e., heavy chain antibodies that bind to one or more non-overlapping epitopes on BCMA protein, PSMA protein, or CD19 protein, such as human BCMA protein, human PSMA protein, or human CD19 protein, as well as heavy chain antibodies that bind to one or more epitopes on BCMA protein, PSMA protein, or CD19 protein, and epitopes on different proteins, such as, for example, CD3 protein. The term "non-overlapping epitope(s)" or "non-competitive epitope(s)" of an antigen is defined herein to mean epitope(s) that are recognized by one member of an antigen-specific antibody pair but not by the other member. Pairs of antibodies that recognize non-overlapping epitopes, or antigen-binding regions that target the same antigen on a multispecific antibody, do not compete for binding to that antigen and can bind to that antigen simultaneously.

[0089] If two antibodies recognize the same or sterically overlapping epitopes, the antibody binds to "essentially the same epitope" as the reference antibody. The most widely used rapid method to determine whether two epitopes bind to the same or sterically overlapping epitopes is a competitive assay, which can be configured in a variety of formats, using either labeled antigen or labeled antibody. Typically, the antigen is immobilized on a 96-well plate, and the ability of unlabeled antibodies to block the binding of labeled antibodies is measured using radioactive or enzymatic labels.

[0090] As used herein, the term "valency" refers to a particular number of binding sites within an antibody molecule.

[0091] A "monovalent" antibody has one binding site. A monovalent antibody is therefore also monospecific.

[0092] A "multivalent" antibody has two or more binding sites. Thus, the terms "bivalent," "trivalent," and "tetravalent" refer to the presence of two binding sites, three binding sites, and four binding sites, respectively. Thus, a bispecific antibody according to the invention is at least bivalent, and may be trivalent, tetravalent, or multivalent. A bivalent antibody according to embodiments of the invention may have two binding sites for the same epitope (i.e., bivalent, monoparatopic), or for two different epitopes (i.e., bivalent, biparatopic).

[0093] A wide variety of methods and protein constructs for preparing bispecific monoclonal antibodies (BsMABs), trispecific antibodies, etc. are known and in use.

[0094] The term "tri-chain antibody-like molecule" or "TCA" is used herein to refer to an antibody-like molecule that comprises, consists essentially of, or consists of three polypeptide subunits, two of which comprise, consist essentially of, or consist of one heavy and one light chain of a monoclonal antibody, or a functional antigen-binding fragment of such antibody chains, comprising an antigen-binding region and at least one CH domain. This heavy / light chain pair has binding specificity for a first antigen. The third polypeptide subunit comprises, consists essentially of, or consists of a heavy chain-only antibody that does not contain a CH1 domain, an Fc portion that contains CH2 and / or CH3 and / or CH4 domains, and an antigen-binding domain that binds to an epitope of a second antigen or a different epitope of the first antigen, such binding domains being derived from or having sequence identity to the variable regions of the heavy or light chains of the antibody. Such variable region portions are V H and / or V L Gene segments, D and J H Gene segment, or J L The variable region can be encoded by a rearranged V H DJ H , V L DJ H , VH J L , or V L J L The TCA protein may be encoded by a gene segment. The TCA protein utilizes a heavy chain-only antibody as defined above.

[0095] The term "chimeric antigen receptor" or "CAR" is used in the broadest sense herein to refer to an engineered receptor that grafts a desired binding specificity (e.g., the antigen-binding region of a monoclonal antibody or other ligand) onto a transmembrane domain and an intracellular signaling domain. Typically, receptors are used to graft the specificity of a monoclonal antibody onto a T cell to create a chimeric antigen receptor (CAR). (J Natl Cancer Inst, 2015; 108(7):dvj439, and Jackson et al., Nature Reviews Clinical Oncology, 2016; 13:370-383). CAR-T cells are T cells that have been genetically engineered to produce an artificial T cell receptor for use in immunotherapy. In one embodiment, "CAR-T cells" refers to therapeutic T cells that express a transgene encoding one or more chimeric antigen receptors that are minimally composed of an extracellular domain, a transmembrane domain, and at least one cytosolic domain.

[0096] The term "human antibody" is used herein to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies herein may include amino acid residues not encoded by human germline immunoglobulin sequences, e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo. The term "human antibody" specifically includes heavy chain-only antibodies having human heavy chain variable region sequences produced by transgenic animals, such as transgenic rats or mice, as defined above, in particular UniAbs™ produced by UniRats™.

[0097] "Chimeric antibody" or "chimeric immunoglobulin" refers to an immunoglobulin molecule that contains amino acid sequences from at least two different Ig loci, e.g., a transgenic antibody that contains a portion encoded by a human Ig locus and a portion encoded by a rat Ig locus. Chimeric antibodies include transgenic antibodies with non-human or artificial Fc regions, and human idiotypes. Such immunoglobulins can be isolated from animals of the invention that have been modified to produce such chimeric antibodies.

[0098] As used herein, the term "effector cell" refers to an immune cell that is involved in the effector stage of an immune response, as opposed to the perception and activation stages of an immune response. Some effector cells express specific Fc receptors and perform specific immune functions. In some embodiments, effector cells, such as natural killer cells, can induce antibody-dependent cellular cytotoxicity (ADCC). For example, monocytes and macrophages that express FcRs are involved in the specific killing of target cells and presenting antigens to other components of the immune system, or binding to cells that present antigens. In some embodiments, effector cells can phagocytose target antigens or target cells.

[0099] "Human effector cells" are leukocytes that express receptors such as T cell receptors and FcRs and perform effector functions. Preferably, these cells express at least FcγRIII and perform ADCC effector functions. Examples of human leukocytes that mediate ADCC include natural killer (NK) cells, monocytes, cytotoxic T cells and neutrophils, with NK cells being preferred. Effector cells can be isolated from their native source, e.g., from blood or PBMCs, as described herein.

[0100] The term "immune cell" is used herein in the broadest sense and includes, but is not limited to, cells of myeloid or lymphoid origin, such as lymphocytes (e.g., B cells and T cells, including cytolytic T cells (CTLs)), killer cells, natural killer (NK) cells, macrophages, monocytes, eosinophils, polymorphonuclear cells, such as neutrophils, granulocytes, mast cells, and basophils.

[0101] An "effector function" of an antibody refers to a biological activity attributable to the Fc region of an antibody (either a native sequence Fc region or an amino acid sequence variant Fc region). Examples of antibody effector functions include C1q binding, complement dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, down-regulation of cell surface receptors (e.g., B cell receptor, BCR), and the like.

[0102] "Antibody-dependent cellular cytotoxicity" and "ADCC" refer to a cell-mediated reaction in which non-specific cytotoxic cells expressing Fc receptors (FcR), such as natural killer (NK) cells, neutrophils, and macrophages, recognize bound antibodies on target cells and subsequently cause lysis of the target cells. NK cells, the primary cells for mediating ADCC, express only FcγRIII, whereas monocytes express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991). To assess ADCC activity of a molecule of interest, an in vitro ADCC assay, such as that described in U.S. Pat. No. 5,500,362 or 5,821,337, may be performed. Effector cells useful for such assays include peripheral blood mononuclear cells (PBMC) and natural killer cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo in an animal model, such as that disclosed in Clynes et al. PNAS (USA) 95:652-656 (1998).

[0103] "Complement-dependent cytotoxicity" or "CDC" refers to the ability of a molecule to lyse a target in the presence of complement. The complement activation pathway is initiated by the binding of the first component of the complement system (C1q) to a molecule (e.g., an antibody) complexed with a cognate antigen. To assess complement activation, a CDC assay may be performed, for example, as described in Gazzano-Santoro et al., J.Immunol.Methods 202:163 (1996).

[0104] "Binding affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise specified, as used herein, "binding affinity" refers to the inherent binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X to its partner Y can generally be represented by a dissociation constant (Kd). Affinity can be measured by common methods known in the art. Low affinity antibodies usually bind antigens slowly and tend to dissociate easily, while high affinity antibodies usually bind antigens faster and tend to remain bound to antigens.

[0105] As used herein, "Kd" or "Kd value" refers to the dissociation constant measured by biolayer interferometry using an Octet QK384 instrument (Fortebio Inc., Menlo Park, CA) in kinetics mode. For example, an anti-mouse Fc sensor is loaded with mouse Fc fusion antigen and immersed in a well containing antibody to measure the concentration-dependent association rate (kon). In the final step of immersing the sensor in a well containing only buffer, the dissociation rate (koff) of the antibody is measured. Kd is the ratio of koff / kon. (For more details, see Concepcion, J, et al., Comb Chem High Throughput Screen, 12(8), 791-800, 2009).

[0106] The terms "treatment", "treating" and the like are generally used herein to mean obtaining a desired pharmacological and / or physiological effect. The effect may be prophylactic in terms of completely or partially preventing the disease or condition, and / or therapeutic in terms of partially or completely curing the disease and / or side effects caused by the disease. As used herein, "treatment" encompasses any treatment of a disease in a mammal, including (a) preventing the onset of the disease in a subject who may be susceptible to the disease but has not yet been diagnosed as having it, (b) inhibiting the disease, i.e., arresting its development, or (c) relieving the disease, i.e., causing regression of the disease. Therapeutic agents may be administered before, during, or after the onset of the disease or injury. Of particular interest are treatments of ongoing diseases where the treatment stabilizes or reduces undesirable clinical symptoms in the patient. It is desirable that such treatments be administered before complete loss of function of the affected tissue. The subject therapeutic agents may be administered during, and in some cases after, the symptomatic phase of the disease.

[0107] By "therapeutically effective amount" is intended the amount of active agent required to provide a therapeutic effect to a subject. For example, a "therapeutically effective amount" is an amount that induces, ameliorates, or causes the improvement of pathological symptoms, disease progression, or physiological conditions associated with a disease, or improves resistance to a disorder.

[0108] As used herein, the term "prostate cancer" refers to a malignant tumor of glandular origin in the prostate gland.

[0109] The term "characterized by PSMA expression" refers broadly to any disease or disorder in which PSMA expression is associated with or involved in one or more pathological processes characteristic of the disease or disorder.Such disorders include, but are not limited to, prostate cancer.

[0110] In the context of the present invention, the term "B cell neoplasm" or "mature B cell neoplasm" includes all lymphocytic leukemias and lymphomas, chronic lymphocytic leukemia, acute lymphoblastic leukemia, prolymphocytic leukemia, precursor B cell lymphoblastic leukemia, hairy cell leukemia, small lymphocytic lymphoma, B cell prolymphocytic lymphoma, B cell chronic lymphocytic leukemia, mantle cell lymphoma, Burkitt's lymphoma, follicular lymphoma, diffuse large B cell lymphoma (DLBCL), multiple myeloma, ... These include, but are not limited to, myeloma, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell neoplasms such as plasma cell myeloma, plasmacytoma, monoclonal immunoglobulin deposition disease, heavy chain disease, MALT lymphoma, nodal marginal zone B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, non-Hodgkin's lymphoma, Hodgkin's lymphoma, hairy cell leukemia, primary pleural effusion lymphoma, and AIDS-related non-Hodgkin's lymphoma.

[0111] The term "characterized by expression of CD19" refers broadly to any disease or disorder in which CD19 expression is associated with or implicated in one or more pathological processes that are characteristic of the disease or disorder. Such disorders include, but are not limited to, B-cell neoplasms.

[0112] The term "characterized by expression of BCMA" refers broadly to any disease or disorder in which BCMA expression is associated with or implicated in one or more pathological processes that are characteristic of the disease or disorder. Such disorders include, but are not limited to, B cell neoplasms.

[0113] The terms "subject," "individual," and "patient" are used interchangeably herein and refer to a mammal being evaluated for and / or treated for therapy. In one embodiment, the mammal is a human. The terms "subject," "individual," and "patient" include, but are not limited to, individuals with cancer, individuals with autoimmune diseases, individuals with pathogen infections, and the like. Subjects can be humans, but also include other mammals, particularly mammals useful as laboratory models of human disease, e.g., mice, rats, and the like.

[0114] The term "pharmaceutical formulation" refers to a formulation in which the biological activity of the active ingredient is in a form such that it is effective, and which does not contain additional ingredients that are unacceptably toxic to the subject to which the formulation is administered. Such formulations are sterile. A "pharmaceutical acceptable" excipient (vehicle, additive) is an excipient that can be reasonably administered to a mammalian subject to provide an effective dose of the active ingredient used.

[0115] A "sterile" formulation is sterile or free or essentially free of all viable microorganisms and their spores. A "frozen" formulation is one whose temperature is below 0°C.

[0116] A "stable" formulation is one in which the protein therein essentially retains its physical and / or chemical stability and / or biological activity upon storage. Preferably, the formulation essentially retains its physical and chemical stability, as well as its biological activity upon storage. The storage period is generally selected based on the intended shelf life of the formulation. A variety of analytical techniques for measuring protein stability are available in the art and are reviewed, for example, in Peptide and Protein Drug Delivery, 247-301. Vincent Lee Ed., Marcel Dekker, Inc., New York, NY, Pubs. (1991) and Jones. A. Adv. Drug Delivery Rev. 10: 29-90) (1993). Stability can be measured at a selected temperature over a selected period of time. Stability may be qualitatively and / or quantitatively assessed in a variety of different ways, including assessment of aggregate formation (e.g., using size exclusion chromatography, by measuring turbidity, and / or by visual inspection), cation exchange chromatography, by assessing charge heterogeneity using image capillary isoelectric focusing (icIEF) or capillary zone electrophoresis, amino- or carboxy-terminal sequence analysis, mass spectrometry, SDS-PAGE analysis comparing reduced and intact antibodies, peptide mapping (e.g., trypsin or LYS-C) analysis, assessment of antibody biological activity or antigen binding function, etc. Instability may include any one or more of aggregation, deamidation (e.g., Asn deamidation), oxidation (e.g., Met oxidation), isomerization (e.g., Asp isomerization), clipping / hydrolysis / fragmentation (e.g., hinge region fragmentation), succinimide formation, unpaired cysteine(s), N-terminal extension, C-terminal processing, differential glycosylation, etc.

[0117] II. Detailed Description

[0118] Anti-BCMA antibody The present invention relates to several families of closely related antibodies that bind to human BCMA. The variable regions of antibodies from these families are described in U.S. Patent Publication Nos. US20190352412, US20200157232 and US20200048348, and PCT Publication Nos. WO2018237037 and WO2019006072, the disclosures of which are incorporated herein by reference in their entireties. A non-limiting selection of representative anti-BCMA heavy chain antibody variable domain sequences is provided in Table 1 below. [Table 1]

[0119] Anti-BCMA antibody sequences may be selected from the antibodies provided herein for development and therapy or other uses, including but not limited to use as multispecific, e.g., bispecific, antibodies. In some embodiments, bispecific or multispecific antibodies are provided, which may have any of the configurations described herein, including but not limited to, TCA. Bispecific antibodies include at least the heavy chain variable region of an antibody specific for a protein other than BCMA.

[0120] Where the protein of the invention is a bispecific antibody, one binding moiety may be specific for human BCMA and the other arm may be specific for a target cell, a tumor associated antigen, a target antigen such as an integrin, a pathogen antigen, a checkpoint protein, etc. Target cells specifically include cancer cells, such as hematological tumors, e.g. B cell tumors, as described below.

[0121] Various formats of bispecific antibodies are within the scope of the present invention, including, but not limited to, single chain polypeptides, two chain polypeptides, three chain polypeptides, four chain polypeptides, and multiples thereof. Bispecific antibodies herein specifically include T cell bispecific antibodies (anti-BCMA x anti-CD3 antibodies) that bind BCMA, which is selectively expressed on plasma cells (PC) and multiple myeloma (MM), and CD3. Such antibodies induce potent T cell-mediated cell death of cells bearing BCMA, and can be used to treat tumors, particularly hematological tumors such as B cell tumors, as further described herein.

[0122] In a preferred embodiment, the bispecific antibody is a TCA comprising an anti-CD3 VH domain paired with a light chain variable domain (VL), the VH and VL domains together having binding affinity for CD3; a heavy chain variable domain of a heavy chain only antibody having binding affinity for BCMA, in a monovalent or bivalent configuration; and a variant human IgG4 Fc domain comprising a first heavy chain constant region sequence comprising S228P, F234A, L235A, and T366W mutations (knob) and a second heavy chain constant region sequence comprising S228P, F234A, L235A, T366S, L368A, and Y407V mutations (hole). This variant, i.e. modified IgG4 Fc domain, prevents unwanted Fab exchange, reduces antibody effector functions, and also promotes heterodimerization of heavy chain polypeptide subunits to form bispecific antibodies.

[0123] In some embodiments, the invention comprises a bispecific antibody comprising i) an anti-CD3 heavy chain comprising SEQ ID NO:56, ii) an anti-CD3 light chain comprising SEQ ID NO:49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO:58.

[0124] In some embodiments, the invention comprises a bispecific antibody comprising i) an anti-CD3 heavy chain comprising SEQ ID NO:56, ii) an anti-CD3 light chain comprising SEQ ID NO:49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO:59.

[0125] In some embodiments, the invention comprises a bispecific antibody comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 56, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 58, wherein the bispecific antibody does not comprise an anti-BCMA light chain.

[0126] In some embodiments, the invention comprises a bispecific antibody comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 56, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 59, wherein the bispecific antibody does not comprise an anti-BCMA light chain.

[0127] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific antibody comprising an anti-CD3 heavy chain comprising SEQ ID NO:56, an anti-CD3 light chain comprising SEQ ID NO:49, and an anti-BCMA heavy chain comprising SEQ ID NO:58.

[0128] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific antibody comprising i) an anti-CD3 heavy chain comprising SEQ ID NO:56, ii) an anti-CD3 light chain comprising SEQ ID NO:49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO:59.

[0129] In some embodiments the invention comprises a human monoclonal IgG4 bispecific antibody comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 56, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and an anti-BCMA heavy chain comprising SEQ ID NO: 58, wherein the bispecific antibody does not comprise an anti-BCMA light chain.

[0130] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific antibody comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 56, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 59, wherein the bispecific antibody does not comprise an anti-BCMA light chain.

[0131] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific antibody comprising (i) a first binding arm that binds human CD3 and (ii) a second binding arm that binds human BCMA, wherein the first binding arm comprises a first heavy chain and a light chain, and the second binding arm comprises a bivalent second heavy chain, wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO: 56, the light chain comprises the amino acid sequence of SEQ ID NO: 49, and the bivalent second heavy chain comprises the amino acid sequence of SEQ ID NO: 58.

[0132] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific antibody comprising (i) a first binding arm that binds human CD3 and (ii) a second binding arm that binds human BCMA, wherein the first binding arm comprises a first heavy chain and a light chain, and the second binding arm comprises a bivalent second heavy chain, wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO:56, the light chain comprises the amino acid sequence of SEQ ID NO:49, and the bivalent second heavy chain comprises the amino acid sequence of SEQ ID NO:59.

[0133] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific antibody comprising (i) a first binding arm that binds human CD3 and (ii) a second binding arm that binds human BCMA, wherein the first binding arm comprises a first heavy chain and a light chain, and the second binding arm comprises a bivalent second heavy chain, wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO: 56, the light chain comprises the amino acid sequence of SEQ ID NO: 49, and the bivalent second heavy chain comprises the amino acid sequence of SEQ ID NO: 58, and the second binding arm does not comprise a light chain.

[0134] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific antibody comprising (i) a first binding arm that binds human CD3 and (ii) a second binding arm that binds human BCMA, wherein the first binding arm comprises a first heavy chain and a light chain, and the second binding arm comprises a bivalent second heavy chain, wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO: 56, the light chain comprises the amino acid sequence of SEQ ID NO: 49, and the bivalent second heavy chain comprises the amino acid sequence of SEQ ID NO: 59, and the second binding arm does not comprise a light chain.

[0135] In some embodiments, the invention comprises a bispecific three-chain antibody-like molecule (TCA) comprising i) an anti-CD3 heavy chain comprising SEQ ID NO:56, ii) an anti-CD3 light chain comprising SEQ ID NO:49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO:58.

[0136] In some embodiments, the invention comprises a bispecific three-chain antibody-like molecule (TCA) comprising i) an anti-CD3 heavy chain comprising SEQ ID NO:56, ii) an anti-CD3 light chain comprising SEQ ID NO:49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO:59.

[0137] In some embodiments, the invention comprises a bispecific three-chain antibody-like molecule (TCA) comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 56, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 58, wherein the bispecific antibody does not comprise an anti-BCMA light chain.

[0138] In some embodiments, the invention comprises a bispecific three-chain antibody-like molecule (TCA) comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 56, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 59, wherein the bispecific antibody does not comprise an anti-BCMA light chain.

[0139] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific three-chain antibody-like molecule (TCA) comprising an anti-CD3 heavy chain comprising SEQ ID NO:56, an anti-CD3 light chain comprising SEQ ID NO:49, and an anti-BCMA heavy chain comprising SEQ ID NO:58.

[0140] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific three-chain antibody-like molecule (TCA) comprising i) an anti-CD3 heavy chain comprising SEQ ID NO:56, ii) an anti-CD3 light chain comprising SEQ ID NO:49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO:59.

[0141] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific three-chain antibody-like molecule (TCA) comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 56, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and an anti-BCMA heavy chain comprising SEQ ID NO: 58, wherein the bispecific antibody does not comprise an anti-BCMA light chain.

[0142] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific three-chain antibody-like molecule (TCA) comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 56, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 59, wherein the bispecific antibody does not comprise an anti-BCMA light chain.

[0143] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific three-chain antibody-like molecule (TCA) comprising (i) a first binding arm that binds to human CD3 and (ii) a second binding arm that binds to human BCMA, wherein the first binding arm comprises a first heavy chain and a light chain, and the second binding arm comprises a bivalent second heavy chain, wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO: 56, the light chain comprises the amino acid sequence of SEQ ID NO: 49, and the bivalent second heavy chain comprises the amino acid sequence of SEQ ID NO: 58.

[0144] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific three-chain antibody-like molecule (TCA) comprising (i) a first binding arm that binds to human CD3 and (ii) a second binding arm that binds to human BCMA, wherein the first binding arm comprises a first heavy chain and a light chain, and the second binding arm comprises a bivalent second heavy chain, wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO: 56, the light chain comprises the amino acid sequence of SEQ ID NO: 49, and the bivalent second heavy chain comprises the amino acid sequence of SEQ ID NO: 59.

[0145] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific three-chain antibody-like molecule (TCA) comprising (i) a first binding arm that binds human CD3 and (ii) a second binding arm that binds human BCMA, wherein the first binding arm comprises a first heavy chain and a light chain, and the second binding arm comprises a bivalent second heavy chain, wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO: 56, the light chain comprises the amino acid sequence of SEQ ID NO: 49, and the bivalent second heavy chain comprises the amino acid sequence of SEQ ID NO: 58, and the second binding arm does not comprise a light chain.

[0146] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific three-chain antibody-like molecule (TCA) comprising (i) a first binding arm that binds human CD3 and (ii) a second binding arm that binds human BCMA, wherein the first binding arm comprises a first heavy chain and a light chain, and the second binding arm comprises a bivalent second heavy chain, wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO: 56, the light chain comprises the amino acid sequence of SEQ ID NO: 49, and the bivalent second heavy chain comprises the amino acid sequence of SEQ ID NO: 59, and the second binding arm does not comprise a light chain.

[0147] In some embodiments, the invention comprises a bispecific antibody comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 75, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 76.

[0148] In some embodiments, the invention comprises a bispecific antibody comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 75, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 77.

[0149] In some embodiments, the invention comprises a bispecific antibody comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 75, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 76, wherein the bispecific antibody does not comprise an anti-BCMA light chain.

[0150] In some embodiments, the invention comprises a bispecific antibody comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 75, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 77, wherein the bispecific antibody does not comprise an anti-BCMA light chain.

[0151] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific antibody comprising an anti-CD3 heavy chain comprising SEQ ID NO:75, an anti-CD3 light chain comprising SEQ ID NO:49, and an anti-BCMA heavy chain comprising SEQ ID NO:76.

[0152] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific antibody comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 75, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 77.

[0153] In some embodiments the invention comprises a human monoclonal IgG4 bispecific antibody comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 75, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and an anti-BCMA heavy chain comprising SEQ ID NO: 76, wherein the bispecific antibody does not comprise an anti-BCMA light chain.

[0154] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific antibody comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 75, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 77, wherein the bispecific antibody does not comprise an anti-BCMA light chain.

[0155] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific antibody comprising (i) a first binding arm that binds human CD3 and (ii) a second binding arm that binds human BCMA, wherein the first binding arm comprises a first heavy chain and a light chain, and the second binding arm comprises a bivalent second heavy chain, wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO: 75, the light chain comprises the amino acid sequence of SEQ ID NO: 49, and the bivalent second heavy chain comprises the amino acid sequence of SEQ ID NO: 76.

[0156] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific antibody comprising (i) a first binding arm that binds human CD3 and (ii) a second binding arm that binds human BCMA, wherein the first binding arm comprises a first heavy chain and a light chain, and the second binding arm comprises a bivalent second heavy chain, wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO: 75, the light chain comprises the amino acid sequence of SEQ ID NO: 49, and the bivalent second heavy chain comprises the amino acid sequence of SEQ ID NO: 77.

[0157] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific antibody comprising (i) a first binding arm that binds human CD3 and (ii) a second binding arm that binds human BCMA, wherein the first binding arm comprises a first heavy chain and a light chain, and the second binding arm comprises a bivalent second heavy chain, wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO: 75, the light chain comprises the amino acid sequence of SEQ ID NO: 49, and the bivalent second heavy chain comprises the amino acid sequence of SEQ ID NO: 76, and the second binding arm does not comprise a light chain.

[0158] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific antibody comprising (i) a first binding arm that binds human CD3 and (ii) a second binding arm that binds human BCMA, wherein the first binding arm comprises a first heavy chain and a light chain, and the second binding arm comprises a bivalent second heavy chain, wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO: 75, the light chain comprises the amino acid sequence of SEQ ID NO: 49, and the bivalent second heavy chain comprises the amino acid sequence of SEQ ID NO: 77, and the second binding arm does not comprise a light chain.

[0159] In some embodiments, the invention comprises a bispecific three-chain antibody-like molecule (TCA) comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 75, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 76.

[0160] In some embodiments, the invention comprises a bispecific three-chain antibody-like molecule (TCA) comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 75, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 77.

[0161] In some embodiments, the invention comprises a bispecific three-chain antibody-like molecule (TCA) comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 75, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 76, wherein the bispecific antibody does not comprise an anti-BCMA light chain.

[0162] In some embodiments, the invention comprises a bispecific three-chain antibody-like molecule (TCA) comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 75, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 77, wherein the bispecific antibody does not comprise an anti-BCMA light chain.

[0163] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific three-chain antibody-like molecule (TCA) comprising an anti-CD3 heavy chain comprising SEQ ID NO: 75, an anti-CD3 light chain comprising SEQ ID NO: 49, and an anti-BCMA heavy chain comprising SEQ ID NO: 76.

[0164] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific three-chain antibody-like molecule (TCA) comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 75, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 77.

[0165] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific three-chain antibody-like molecule (TCA) comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 75, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and an anti-BCMA heavy chain comprising SEQ ID NO: 76, wherein the bispecific antibody does not comprise an anti-BCMA light chain.

[0166] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific three-chain antibody-like molecule (TCA) comprising i) an anti-CD3 heavy chain comprising SEQ ID NO: 75, ii) an anti-CD3 light chain comprising SEQ ID NO: 49, and iii) an anti-BCMA heavy chain comprising SEQ ID NO: 77, wherein the bispecific antibody does not comprise an anti-BCMA light chain.

[0167] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific three-chain antibody-like molecule (TCA) comprising (i) a first binding arm that binds to human CD3 and (ii) a second binding arm that binds to human BCMA, wherein the first binding arm comprises a first heavy chain and a light chain, and the second binding arm comprises a bivalent second heavy chain, wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO: 75, the light chain comprises the amino acid sequence of SEQ ID NO: 49, and the bivalent second heavy chain comprises the amino acid sequence of SEQ ID NO: 76.

[0168] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific three-chain antibody-like molecule (TCA) comprising (i) a first binding arm that binds to human CD3 and (ii) a second binding arm that binds to human BCMA, wherein the first binding arm comprises a first heavy chain and a light chain, and the second binding arm comprises a bivalent second heavy chain, wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO: 75, the light chain comprises the amino acid sequence of SEQ ID NO: 49, and the bivalent second heavy chain comprises the amino acid sequence of SEQ ID NO: 77.

[0169] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific three-chain antibody-like molecule (TCA) comprising (i) a first binding arm that binds human CD3 and (ii) a second binding arm that binds human BCMA, wherein the first binding arm comprises a first heavy chain and a light chain, and the second binding arm comprises a bivalent second heavy chain, wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO: 75, the light chain comprises the amino acid sequence of SEQ ID NO: 49, and the bivalent second heavy chain comprises the amino acid sequence of SEQ ID NO: 76, and the second binding arm does not comprise a light chain.

[0170] In some embodiments, the invention comprises a human monoclonal IgG4 bispecific three-chain antibody-like molecule (TCA) comprising (i) a first binding arm that binds human CD3 and (ii) a second binding arm that binds human BCMA, wherein the first binding arm comprises a first heavy chain and a light chain, and the second binding arm comprises a bivalent second heavy chain, wherein the first heavy chain comprises the amino acid sequence of SEQ ID NO: 75, the light chain comprises the amino acid sequence of SEQ ID NO: 49, and the bivalent second heavy chain comprises the amino acid sequence of SEQ ID NO: 77, and the second binding arm does not comprise a light chain.

[0171] Anti-CD19 antibody The present invention provides a family of closely related antibodies that bind to human CD19. The variable regions of the antibodies of this family are described in PCT Publication No. WO2020018922, the disclosure of which is incorporated herein by reference in its entirety. Anti-CD19 antibody sequences can be selected from the sequences provided herein for development and therapeutic or other uses, including but not limited to use as multispecific, e.g., bispecific, antibodies. In some embodiments, bispecific or multispecific antibodies are provided, which can have any of the configurations described herein, including but not limited to TCA. Bispecific antibodies include at least the heavy chain variable region of an antibody specific for a protein other than CD19.

[0172] When the protein of the invention is a bispecific antibody, one binding moiety may be specific for human CD19, while the other arm may be specific for a target cell, a tumor-associated antigen, a target antigen, such as an integrin, a pathogen antigen, a checkpoint protein, etc. Target cells specifically include cancer cells, such as hematological tumors, such as B-cell tumors, as described below.

[0173] Various formats of bispecific antibodies are within the scope of the present invention, including but not limited to single chain polypeptides, two chain polypeptides, three chain polypeptides, four chain polypeptides, and multiples thereof. Bispecific antibodies herein specifically include T cell bispecific antibodies (anti-CD19 x anti-CD3 antibodies) that bind CD19 and CD3, which are selectively expressed on mature B cells. Such antibodies, as further described herein, can be used to induce potent T cell-mediated cell death of cells expressing CD19 and treat tumors, particularly hematological tumors such as B cell tumors.

[0174] In a preferred embodiment, the bispecific antibody is a TCA comprising an anti-CD3 VH domain paired with a light chain variable domain (VL), the VH and VL domains together having binding affinity for CD3; a heavy chain variable domain of a heavy chain only antibody having binding affinity for CD19, in a monovalent or bivalent configuration; and a variant human IgG4 Fc domain comprising a first heavy chain constant region sequence comprising S228P, F234A, L235A, and T366W mutations (knob) and a second heavy chain constant region sequence comprising S228P, F234A, L235A, T366S, L368A, and Y407V mutations (hole). This variant, i.e. modified IgG4 Fc domain, prevents unwanted Fab exchange, reduces antibody effector functions, and also promotes heterodimerization of heavy chain polypeptide subunits to form bispecific antibodies.

[0175] Anti-PSMA antibody The present invention provides a family of closely related antibodies that bind to human PSMA. Antibodies in this family are exemplified by the provided heavy chain variable region (VH) sequences in SEQ ID NOs: 24-54 shown in Table 2. This family of antibodies offers many advantages that contribute to their usefulness as clinical therapeutic drug(s). The antibodies include members with a range of binding affinities, such that a particular sequence with a desired binding affinity can be selected. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4]

[0176] In a preferred embodiment, the bispecific antibody is a TCA comprising an anti-CD3 VH domain paired with a light chain variable domain (VL), the VH and VL domains together having binding affinity for CD3; a heavy chain variable domain of a heavy chain-only antibody, in a monovalent or bivalent configuration, having binding affinity for PSMA; and a variant human IgG4 Fc domain comprising a first heavy chain constant region sequence comprising S228P, F234A, L235A, and T366W mutations (knob) and a second heavy chain constant region sequence comprising S228P, F234A, L235A, T366S, L368A, and Y407V mutations (hole). This variant, i.e. modified IgG4 Fc domain, prevents unwanted Fab exchange, reduces antibody effector functions, and also promotes heterodimerization of heavy chain polypeptide subunits to form bispecific antibodies.

[0177] CD3×target protein triple-chain antibody-like molecule (TCA) In some embodiments, bispecific or multispecific antibodies are provided, which may have any of the configurations described herein, including, but not limited to, bispecific three-chain antibody-like molecules. In some embodiments, the multispecific antibody may comprise a heavy / light chain pair having binding specificity for a first antigen (e.g., CD3) and a heavy chain derived from a heavy chain-only antibody. In certain embodiments, the heavy chain derived from a heavy chain-only antibody does not comprise a CH1 domain and comprises an Fc portion comprising a CH2 and / or CH3 and / or CH4 domain. In one particular embodiment, the bispecific antibody comprises a heavy / light chain pair having binding specificity for an antigen on an effector cell (e.g., CD3 protein on a T cell) and a heavy chain derived from a heavy chain-only antibody comprising an antigen binding domain having binding specificity for BCMA, PSMA, or CD19.

[0178] In a preferred embodiment, the bispecific antibody is a TCA comprising an anti-CD3 VH domain paired with a light chain variable domain (VL), the VH and VL domains together having binding affinity for CD3; a heavy chain variable domain of a heavy chain only antibody having binding affinity for BCMA, PSMA, or CD19; a variant human IgG4 Fc domain comprising a first heavy chain constant region sequence comprising S228P, F234A, L235A, and T366W mutations (knob) and a second heavy chain constant region sequence comprising S228P, F234A, L235A, T366S, L368A, and Y407V mutations (hole). This variant, i.e. modified IgG4 Fc domain, prevents unwanted Fab exchange, reduces antibody effector functions, and also promotes heterodimerization of heavy chain polypeptide subunits to form bispecific antibodies.

[0179] In some embodiments, the multispecific antibody comprises a CD3-binding VH domain paired with a light chain variable domain. In certain embodiments, the light chain is a fixed light chain. In some embodiments, the CD3-binding VH domain comprises a CDR1 sequence of SEQ ID NO: 36, a CDR2 sequence of SEQ ID NO: 37, and a CDR3 sequence of SEQ ID NO: 38, in a human VH framework. In some embodiments, the fixed light chain comprises a CDR1 sequence of SEQ ID NO: 39, a CDR2 sequence of SEQ ID NO: 40, and a CDR3 sequence of SEQ ID NO: 41, in a human VL framework. Together, the CD3-binding VH domain and the light chain variable domain have binding affinity for CD3. In some embodiments, the CD3-binding VH domain comprises a heavy chain variable region sequence of SEQ ID NO: 42. In some embodiments, the CD3-binding VH domain comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% identity to the heavy chain variable region sequence of SEQ ID NO: 42. In some embodiments, the fixed light chain comprises a light chain variable region sequence of SEQ ID NO: 43. In some embodiments, the fixed light chain comprises a sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99% identity to the heavy chain variable region sequence of SEQ ID NO: 43.

[0180] Multispecific antibodies comprising the above CD3-binding VH domains and light chain variable domains have advantageous properties, for example as described in PCT Publication No. WO2018 / 052503, the disclosure of which is incorporated herein by reference in its entirety. Any of the multispecific antibodies and antigen-binding domains described herein that have binding affinity for BCMA, PSMA, or CD19 can be combined with the CD3-binding domains and fixed light chain domains described herein to generate multispecific antibodies with binding affinity for one or more BCMA epitopes, PSMA epitopes, or CD19 epitopes and CD3. [Table 3] [Table 4]

Table 5

Table 6-1

Table 6-2

Table 6-3

Table 7-1

Table 7-2

Table 7-3

Table 7-4

Table 7-5

Table 7-6

Table 7-7

Table 7-8

Table 7-9

[0181] In some embodiments, bispecific or multispecific antibodies are provided, which may have any of the configurations described herein, including, but not limited to, bispecific three-chain antibody-like molecules. In some embodiments, a bispecific antibody may comprise at least one heavy chain variable region with binding specificity for BCMA, PSMA, or CD19, and at least one heavy chain variable region with binding specificity for a different protein, e.g., CD3. In some embodiments, a bispecific antibody may comprise, in a monovalent or bivalent configuration, a heavy chain / light chain pair with binding specificity for a first antigen, and a heavy chain from a heavy chain-only antibody that comprises an Fc portion that does not comprise a CH1 domain and comprises a CH2 and / or CH3 and / or CH4 domain, and an antigen binding domain that binds to an epitope of a second antigen or a different epitope of a first antigen. In one specific embodiment, a bispecific antibody comprises, in a monovalent or bivalent configuration, a heavy chain / light chain pair that has binding specificity for an antigen on an effector cell (e.g., CD3 protein on a T cell), and a heavy chain from a heavy chain-only antibody that contains an antigen-binding domain that has binding specificity for BCMA, PSMA, or CD19.

[0182] In some embodiments where the antibody of the present invention is a bispecific antibody, one arm of the antibody (one binding moiety or one binding unit) may be specific for human BCMA, human PSMA, or human CD19, and the other arm may be specific for a target cell, a tumor-associated antigen, a targeting antigen, such as an integrin, a pathogen antigen, a checkpoint protein, or the like. Target cells specifically include, but are not limited to, cancer cells, including cells from solid tumors, such as prostate tumors, as described below. In some embodiments, one arm of the antibody (one binding moiety or one binding unit) is specific for human BCMA, human PSMA, or human CD19, and the other arm is specific for CD3.

[0183] In some embodiments, the antibody comprises an anti-CD3 light chain polypeptide comprising the sequence of SEQ ID NO: 43 linked to the sequence of SEQ ID NO: 48, an anti-CD3 heavy chain polypeptide comprising the sequence of any one of SEQ ID NOs: 44, 45, 46, 47, 50, 51, 52, 53, 56 or 57, and an anti-BCMA heavy chain polypeptide comprising the sequence of any one of SEQ ID NOs: 58, 59 or 60 in a monovalent or bivalent configuration linked to the sequence of any one of SEQ ID NOs: 75, 76, 77, 78, 84 or 85. In a preferred embodiment, the antibody is a TCA comprising a first polypeptide comprising SEQ ID NO: 49, a second polypeptide comprising SEQ ID NO: 56, and a third polypeptide comprising SEQ ID NO: 58, 59 or 60. In a preferred embodiment, the antibody is a TCA comprising a first polypeptide comprising SEQ ID NO: 49, a second polypeptide comprising SEQ ID NO: 56, and a third polypeptide comprising SEQ ID NO: 58. In a preferred embodiment, the antibody is a TCA consisting of a first polypeptide consisting of SEQ ID NO: 49, a second polypeptide consisting of SEQ ID NO: 56, and a third polypeptide consisting of SEQ ID NO: 58. In a preferred embodiment, the antibody is a TCA consisting of a first polypeptide comprising SEQ ID NO: 49, a second polypeptide comprising SEQ ID NO: 56, and a third polypeptide comprising SEQ ID NO: 59. In a preferred embodiment, the antibody is a TCA consisting of a first polypeptide consisting of SEQ ID NO: 49, a second polypeptide comprising SEQ ID NO: 56, and a third polypeptide consisting of SEQ ID NO: 59. In a preferred embodiment, the antibody is a TCA consisting of a first polypeptide consisting of SEQ ID NO: 49, a second polypeptide comprising SEQ ID NO: 56, and a third polypeptide consisting of SEQ ID NO: 60. In a preferred embodiment, the antibody is a TCA consisting of a first polypeptide consisting of SEQ ID NO: 49, a second polypeptide comprising SEQ ID NO: 56, and a third polypeptide consisting of SEQ ID NO: 60.

[0184] In some embodiments, the antibody comprises an anti-CD3 light chain polypeptide comprising the sequence of SEQ ID NO: 43 linked to the sequence of SEQ ID NO: 48, an anti-CD3 heavy chain polypeptide comprising the sequence of any one of SEQ ID NOs: 44, 45, 46, 47, 50, 51, 52, 53, 56 or 57, and an anti-PSMA heavy chain polypeptide comprising the sequence of any one of SEQ ID NOs: 61, 62, 63, 64, 65 or 66. In a preferred embodiment, the antibody is a TCA comprising a first polypeptide comprising SEQ ID NO: 49, a second polypeptide comprising SEQ ID NO: 56, and a third polypeptide comprising SEQ ID NO: 61. In a preferred embodiment, the antibody is a TCA comprising a first polypeptide consisting of SEQ ID NO: 49, a second polypeptide consisting of SEQ ID NO: 56, and a third polypeptide consisting of SEQ ID NO: 61. In a preferred embodiment, the antibody is a TCA comprising a first polypeptide consisting of SEQ ID NO: 49, a second polypeptide consisting of SEQ ID NO: 56, and a third polypeptide consisting of SEQ ID NO: 62. In a preferred embodiment, the antibody is a TCA consisting of a first polypeptide consisting of SEQ ID NO: 49, a second polypeptide consisting of SEQ ID NO: 56, and a third polypeptide consisting of SEQ ID NO: 62. In a preferred embodiment, the antibody is a TCA consisting of a first polypeptide comprising SEQ ID NO: 49, a second polypeptide comprising SEQ ID NO: 56, and a third polypeptide comprising SEQ ID NO: 63. In a preferred embodiment, the antibody is a TCA consisting of a first polypeptide consisting of SEQ ID NO: 49, a second polypeptide comprising SEQ ID NO: 56, and a third polypeptide comprising SEQ ID NO: 63. In a preferred embodiment, the antibody is a TCA consisting of a first polypeptide consisting of SEQ ID NO: 49, a second polypeptide comprising SEQ ID NO: 56, and a third polypeptide comprising SEQ ID NO: 64. In a preferred embodiment, the antibody is a TCA consisting of a first polypeptide consisting of SEQ ID NO: 49, a second polypeptide comprising SEQ ID NO: 56, and a third polypeptide comprising SEQ ID NO: 64. In a preferred embodiment, the antibody is a TCA consisting of a first polypeptide consisting of SEQ ID NO: 49, a second polypeptide comprising SEQ ID NO: 56, and a third polypeptide comprising SEQ ID NO: 65.In a preferred embodiment, the antibody is a TCA consisting of a first polypeptide consisting of SEQ ID NO: 49, a second polypeptide consisting of SEQ ID NO: 56, and a third polypeptide consisting of SEQ ID NO: 65. In a preferred embodiment, the antibody is a TCA consisting of a first polypeptide comprising SEQ ID NO: 49, a second polypeptide comprising SEQ ID NO: 56, and a third polypeptide comprising SEQ ID NO: 66. In a preferred embodiment, the antibody is a TCA consisting of a first polypeptide consisting of SEQ ID NO: 49, a second polypeptide consisting of SEQ ID NO: 56, and a third polypeptide consisting of SEQ ID NO: 66.

[0185] In some embodiments, the antibody comprises an anti-CD3 light chain polypeptide comprising the sequence of SEQ ID NO: 43 linked to the sequence of SEQ ID NO: 48, an anti-CD3 heavy chain polypeptide comprising the sequence of any one of SEQ ID NOs: 44, 45, 46, 47, 50, 51, 52, 53, 56 or 57, and an anti-CD19 heavy chain polypeptide comprising the sequence of any one of SEQ ID NOs: 67, 68 or 69. In a preferred embodiment, the antibody is a TCA comprising a first polypeptide comprising SEQ ID NO: 49, a second polypeptide comprising SEQ ID NO: 56, and a third polypeptide comprising SEQ ID NO: 67. In a preferred embodiment, the antibody is a TCA comprising a first polypeptide consisting of SEQ ID NO: 49, a second polypeptide consisting of SEQ ID NO: 56, and a third polypeptide consisting of SEQ ID NO: 67. In a preferred embodiment, the antibody is a TCA comprising a first polypeptide consisting of SEQ ID NO: 49, a second polypeptide consisting of SEQ ID NO: 56, and a third polypeptide consisting of SEQ ID NO: 68. In a preferred embodiment, the antibody is a TCA consisting of a first polypeptide consisting of SEQ ID NO: 49, a second polypeptide consisting of SEQ ID NO: 56, and a third polypeptide consisting of SEQ ID NO: 68. In a preferred embodiment, the antibody is a TCA consisting of a first polypeptide comprising SEQ ID NO: 49, a second polypeptide comprising SEQ ID NO: 56, and a third polypeptide comprising SEQ ID NO: 69. In a preferred embodiment, the antibody is a TCA consisting of a first polypeptide consisting of SEQ ID NO: 49, a second polypeptide consisting of SEQ ID NO: 56, and a third polypeptide consisting of SEQ ID NO: 69.

[0186] Various forms of multispecific antibodies are within the scope of the present invention, including, but not limited to, single chain polypeptides, two chain polypeptides, three chain polypeptides, four chain polypeptides, and multiples thereof. The multispecific antibodies herein specifically include T cell multispecific (e.g., bispecific) antibodies that bind BCMA, PSMA, or 19, and CD3 (anti-BCMA x anti-CD3 antibodies, anti-PSMA x anti-CD3 antibodies, anti-CD19 x anti-CD3 antibodies), and comprise a variant human IgG4 Fc domain comprising a first heavy chain constant region sequence comprising S228P, F234A, L235A, and T366W mutations (knob), and a second heavy chain constant region sequence comprising S228P, F234A, L235A, T366S, L368A, and Y407V mutations (hole). This variant, a modified IgG4 Fc domain, prevents unwanted Fab exchange, reduces antibody effector function, and promotes heterodimerization of heavy chain polypeptide subunits to form bispecific antibodies. Such antibodies induce potent T cell-mediated cell death of cells expressing BCMA, PSMA, or CD19, respectively.

[0187] Preparation of antibodies The multispecific antibodies of the present invention can be prepared by methods known in the art. In a preferred embodiment, the heavy chain antibodies of the present invention are produced by transgenic animals, including transgenic mice and rats, preferably rats, in which the endogenous immunoglobulin genes have been knocked out or disabled. In a preferred embodiment, the heavy chain antibodies of the present invention are produced in UniRat™, which has silenced endogenous immunoglobulin genes and expresses a diverse and naturally optimized repertoire of fully human HCAbs using a human immunoglobulin heavy chain transgene locus. While rat endogenous immunoglobulin loci can be knocked out or silenced using a variety of techniques, in UniRat™, zinc finger (endo)nuclease (ZNF) technology was used to inactivate the endogenous rat heavy chain J locus, light chain Cκ locus and light chain Cλ locus. ZNF constructs for microinjection into oocytes can generate IgH and IgL knockout (KO) lines. For details, see, e.g., Geurts et al., 2009, Science 325:433. Characterization of Ig heavy chain knockout rats has been reported by Menoret et al., 2010, Eur. J. Immunol. 40:2932-2941. An advantage of ZNF technology is that non-homologous end joining to silence genes or loci through deletions of up to several kb can also provide target sites for homologous integration (Cui et al., 2011, Nat Biotechnol 29:64-67). Human heavy chain antibodies produced in UniRat™ are called UniAbs™ and can bind epitopes that cannot be attacked by conventional antibodies. Their high specificity, affinity, and small size make them ideal for mono- and multispecific applications.

[0188] In addition to UniAbs™, specifically included herein are camelid VHH frameworks and mutations, as well as heavy chain-only antibodies lacking their functional VH regions. Such heavy chain-only antibodies can be produced in transgenic rats or mice containing a fully human heavy chain-only locus, for example as described in WO2006 / 008548, although other transgenic mammals such as rabbits, guinea pigs, rats, etc. can also be used, with rats and mice being preferred. Heavy chain-only antibodies comprising VHH or VH functional fragments can also be produced by recombinant DNA technology, for example by expressing the encoding nucleic acid in a suitable eukaryotic or prokaryotic host, including mammalian cells (e.g., CHO cells), E. coli, or yeast.

[0189] Heavy chain-only antibody domains combine the advantages of antibodies and small molecule drugs, can be monovalent or polyvalent, have low toxicity and are cost-effective to produce. Due to their small size, these domains are easy to administer, including orally or topically, feature high stability, including gastrointestinal stability, and their half-life can be tailored to the desired application or indication. Furthermore, VH and VHH domains of HCAbs can be produced in a cost-effective manner.

[0190] In certain embodiments, the heavy chain antibodies of the invention, including UniAbs™, have a substitution of the native amino acid residue at the first position of the FR4 region (amino acid position 101 according to the Kabat numbering system) with another amino acid residue, which may disrupt a surface-exposed hydrophobic patch that includes or is associated with the native amino acid residue at that position. Such a hydrophobic patch is normally buried at the interface with the light chain constant region of the antibody, but is surface-exposed in the HCAb and is used, at least in part, for undesired aggregation of the HCAb and association with the light chain. The substituted amino acid residue is preferably charged, more preferably positively charged, such as lysine (Lys, K), arginine (Arg, R) or histidine (His, H), preferably arginine (R). In a preferred embodiment, the heavy chain-only antibody derived from the transgenic animal contains a Trp to Arg mutation at position 101. The resulting HCAb preferably has high antigen binding affinity and solubility under physiological conditions without aggregation.

[0191] As part of the present invention, human heavy chain antibodies (UniAbs™) with unique sequences derived from UniRat™ animals have been identified that bind to human CD3, BCMA, PSMA, or CD19 in ELISA protein and cell binding assays. The identified heavy chain variable region (VH) sequences (see, e.g., Tables 1 and 2) are all positive for protein binding and / or binding to cells expressing the target protein (e.g., CD3, BCMA, PSMA, or CD19) and negative for binding to cells not expressing the target protein.

[0192] Heavy chain antibodies, e.g., UniAbs™, that bind non-overlapping epitopes on a target protein can be identified by competitive binding assays, such as enzyme-linked immunosorbent assays (ELISA assays) or flow cytometry competitive binding assays. For example, competition between a known antibody that binds to a target antigen and an antibody of interest can be used. Using this approach, a set of antibodies can be classified into those that compete with a reference antibody and those that do not. Non-competing antibodies are identified as binding to distinct epitopes that do not overlap with the epitope bound by the reference antibody. Often, one antibody is immobilized and allowed to bind the antigen, and a second, labeled (e.g., biotinylated) antibody is tested in an ELISA assay for its ability to bind to the captured antigen. This can also be performed using surface plasmon resonance (SPR) platforms such as the ProteOn XPR36 (BioRad, Inc), Biacore 2000 and Biacore T200 (GE Healthcare Life Sciences), and MX96 SPR Imager (Ibis Technologies BV), as well as biolayer interferometry platforms such as Octet Red384 and Octet HTX (ForteBio, Pall Inc). See the Examples herein for further details.

[0193] Generally, an antibody "competes" with a reference antibody if it causes about a 15-100% reduction in binding of the reference antibody to a target antigen as measured by standard techniques such as the competitive binding assays described above. In various embodiments, the relative inhibition is at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% or more.

[0194] Pharmaceutical Compositions, Uses and Methods of Treatment It is another aspect of the present invention to provide a pharmaceutical composition comprising one or more multispecific binding compounds of the present invention in admixture with a suitable pharma- ceutically acceptable carrier. As used herein, a pharma- ceutically acceptable carrier is exemplified by, but not limited to, an adjuvant, a solid carrier, water, a buffer, or other carrier used in the art to carry therapeutic ingredients, or a combination thereof.

[0195] In one embodiment, the pharmaceutical composition comprises a heavy chain antibody (e.g., UniAb™) that binds to a target protein (e.g., CD3, BCMA, PSMA, or CD19). In another embodiment, the pharmaceutical composition comprises a multispecific (including bispecific) heavy chain antibody (e.g., UniAb™) that has binding specificity for two or more non-overlapping epitopes on a target protein (e.g., CD3, BCMA, PSMA, or CD19). In a preferred embodiment, the pharmaceutical composition comprises a multispecific (including bispecific) heavy chain antibody (e.g., UniAb™) that has binding specificity for a target protein (e.g., CD3, BCMA, PSMA, or CD19) and binding specificity for a binding target on an effector cell (e.g., a binding target on a T cell, e.g., CD3 protein on a T cell).

[0196] Pharmaceutical compositions of antibodies used according to the present invention are prepared for storage, for example in the form of a lyophilized formulation or aqueous solution, by mixing the protein with the desired purity with optional pharma- ceutically acceptable carriers, excipients, or stabilizers (see, for example, Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)). Acceptable carriers, excipients, or stabilizers are non-toxic to recipients at the dosages and concentrations used, and include buffers such as phosphate, citrate, and other organic acids, antioxidants including ascorbic acid and methionine, preservatives (such as octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl, or benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol), low molecular weight (less than about 10 residues) polypeptides, serum albumin, These include proteins such as gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as TWEEN™, PLURONICS™, or polyethylene glycol (PEG).

[0197] Pharmaceutical compositions for oral administration are preferably sterile, substantially isotonic, and manufactured under Good Manufacturing Practice (GMP) conditions. Pharmaceutical compositions can be provided in unit dosage form (i.e., single-administration doses). Formulation depends on the route of administration selected. The antibodies herein can be administered by intravenous injection or infusion, or subcutaneously. For administration by injection, the antibodies herein can be formulated in an aqueous solution, preferably in a physiologically compatible buffer, to reduce discomfort at the injection site. The solution can contain carriers, excipients, or stabilizers, as described above. Alternatively, the antibodies can be in lyophilized form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[0198] Antibody formulations are disclosed, for example, in US Patent No. 9,034,324. Similar formulations can be used for heavy chain antibodies, including the UniAbs™, of the present invention. Subcutaneous antibody formulations are described, for example, in US20160355591 and US20160166689.

[0199] How to use The heavy chain-only antibodies, multispecific antibodies, and pharmaceutical compositions described herein can be used to treat diseases and conditions characterized by expression of a target protein (e.g., CD3, BCMA, PSMA, or CD19), including, but not limited to, the conditions and diseases further described herein.

[0200] The pharmaceutical compositions herein comprising anti-BCMA antibodies can be used to treat B cell related disorders including B cell and plasma cell malignancies and autoimmune disorders characterized by expression or overexpression of BCMA.

[0201] Such B cell related disorders include, but are not limited to, plasmacytoma, Hodgkin's lymphoma, follicular lymphoma, small non-cleaved cell lymphoma, regional Burkitt lymphoma, sporadic Burkitt lymphoma, marginal zone lymphoma, extranodal mucosa-associated lymphoid tissue lymphoma, nodular monocytoid B cell lymphoma, splenic lymphoma, mantle cell lymphoma, large cell lymphoma, diffuse mixed cell lymphoma, immunoblastic lymphoma, primary mediastinal B cell lymphoma, pulmonary B cell angiocentric lymphoma, small lymphocytic lymphoma, potentially malignant B cell proliferation, lymphomatoid granulomatosis, post-transplant lymphoma, Proliferative disorders, immunoregulatory disorders, rheumatoid arthritis, myasthenia gravis, idiopathic thrombocytopenic purpura, antiphospholipid syndrome, Chagas disease, Grave's disease, Wegener's granulomatosis, polyarteritis nodosa, Sjogren's syndrome, pemphigus vulgaris, scleroderma, multiple sclerosis, antiphospholipid syndrome, ANCA-associated vasculitis, Goodpasture's disease, Kawasaki disease, autoimmune hemolytic anemia, and B-cell and plasma cell malignancies including rapidly progressive glomerulonephritis, heavy chain disease, primary or immune cell-associated amyloidosis, or monoclonal gammopathy, and autoimmune diseases.

[0202] Plasma cell disorders characterized by BCMA expression include multiple myeloma (MM). MM is a B-cell malignancy characterized by monoclonal proliferation and accumulation of abnormal plasma cells in the bone marrow compartment. Current therapies for MM often induce remission, but nearly all patients eventually relapse and die. There is substantial evidence that myeloma cells can be eliminated through immune-mediated means in the setting of allogeneic hematopoietic stem cell transplantation; however, this approach is highly toxic and few patients are cured. Although some monoclonal antibodies have shown promise in the treatment of MM in preclinical studies and early clinical trials, consistent clinical efficacy of monoclonal antibody therapy for MM has not been conclusively proven. Thus, there is a great need for novel therapies, including immunotherapy, for MM (see, e.g., Carpenter et al., Clin Cancer Res 2013,19(8):2048-2060).

[0203] Overexpression or activation of BCMA by its proliferation-inducing ligand, APRIL, is known to promote human multiple myeloma (MM) progression in vivo. BCMA has also been shown to promote the in vivo growth of xenografted MM cells carrying p53 mutations in mice. Because activity of the APRIL / BCMA pathway plays a central role in MM pathogenesis and drug resistance through bidirectional interactions between tumor cells and their supporting bone marrow microenvironment, BCMA has been identified as a therapeutic target for MM. For further details, see, e.g., Yu-Tsu Tai et al., Blood 2016;127(25):3225-3236.

[0204] Another B-cell disorder involving plasma cells, i.e. expressing BCMA, is systemic lupus erythematosus (SLE), also known as lupus. SLE is a systemic autoimmune disease that can affect any part of the body, typically resulting in the immune system attacking the body's own cells and tissues, causing chronic inflammation and tissue damage. This is a type III hypersensitivity reaction in which antibody-immune complexes precipitate and trigger further immune responses (Inaki & Lee, Nat Rev Rheumatol 2010;6:326-337).

[0205] The anti-BCMA heavy chain only antibodies (UniAbs) of the invention can be used to develop therapeutics for the treatment of MM, SLE, and other B cell or plasma cell disorders characterized by expression of BCMA, such as those listed above. In particular, the anti-BCMA heavy chain only antibodies (UniAbs) of the invention are candidates for treating MM, either alone or in combination with other MM therapies.

[0206] PSMA is a type II transmembrane protein that is expressed in prostate epithelial tissue and upregulated in the neovasculature of prostate cancer and solid tumors. It is also expressed at low levels in healthy tissues such as the brain, kidney, and salivary glands, but its overexpression in malignant prostate tissue makes it an attractive target for therapeutic treatment of prostate cancer. Its high expression in malignant neovasculature may also make it suitable for the treatment or imaging of solid tumors. Monoclonal antibodies, antibody-drug conjugates, and chimeric antigen receptor T cells targeting PSMA have been described for the treatment of metastatic prostate cancer (Hernandez-Hoyos et al. 2016, PMID:27406985; DiPippo et al. 2014, PMID:25327986; Serganova et al. 2016, PMID:28345023). Additionally, PSMA-specific radionuclide conjugates are being investigated for prostate cancer imaging and treatment (e.g., Hofman et al., 2018 PMID:29752180).

[0207] In one aspect, the PSMA heavy chain antibodies (e.g., UniAbs™) and pharmaceutical compositions herein can be used to treat disorders characterized by expression of PSMA, including, but not limited to, prostate cancer and solid tumors.

[0208] CD19 is a cell surface receptor expressed on all human B cells, but is not found on plasma cells. CD19 has a relatively large 240 amino acid cytoplasmic tail. The extracellular Ig-like domain is separated by a potential disulfide-linked non-Ig-like domain and an N-linked carbohydrate attachment site. The cytoplasmic tail contains at least nine tyrosine residues near the C-terminus, some of which have been shown to be phosphorylated. The restricted expression of CD19, in addition to CD20 and CD22, to the B cell lineage makes it an attractive target for therapeutic treatment of B cell malignancies. CD19 is a promising target for antibody-based therapy, as its expression has been observed in many hematological malignancies.

[0209] In one aspect, the CD19 heavy chain antibodies (e.g., UniAbs™) and pharmaceutical compositions herein can be used to treat hematological malignancies characterized by expression of CD19, including, but not limited to, diffuse large B-cell lymphoma (DLBCL), non-Hodgkin's lymphoma, B-cell chronic lymphocytic leukemia (CLL), and B-cell acute lymphoblastic leukemia (ALL).

[0210] Diffuse large B-cell lymphoma (DLBCL or DLBL) is the most common form of non-Hodgkin's lymphoma in adults (Blood 1997 89(11):3909-18), with an estimated annual incidence of 7-8 cases per 100,000 people per year in the United States and the United Kingdom. It is characterized as an aggressive cancer that can arise in virtually any part of the body. The causes of DLBCL are poorly understood and can arise from malignant transformation of normal B cells as well as other types of lymphoma or leukemia cells. Treatment approaches generally include chemotherapy and radiation therapy, with an overall average 5-year survival rate of approximately 58% in adults. Some monoclonal antibodies have shown promise in the treatment of DLBCL, but consistent clinical efficacy has yet to be conclusively proven. Thus, novel therapies for DLBCL, including immunotherapy, are greatly needed.

[0211] In another aspect, the CD19 heavy chain antibodies (e.g., UniAbs™) and pharmaceutical compositions herein can be used to treat autoimmune disorders characterized by pathogenic B cells that express CD19, including, but not limited to, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS).

[0212] The effective dose of the composition of the present invention for treating a disease varies depending on many different factors, including the means of administration, the target site, the physiological condition of the patient, whether the patient is human or animal, other drugs administered, and whether the treatment is prophylactic or therapeutic. Typically, the patient is a human, but non-human mammals, such as companion animals, e.g., dogs, cats, horses, and laboratory mammals, e.g., rabbits, mice, rats, and the like, may also be treated. Treatment doses may be titrated to optimize safety and efficacy.

[0213] Dosage level can be easily determined by those skilled in the art, but can be changed as needed, for example, as needed to change the subject's response to treatment. The amount of active ingredient that can be combined with carrier material to produce a single dosage form varies depending on the host treated and the specific mode of administration. Generally, a unit dosage form contains about 1 mg to about 500 mg of active ingredient.

[0214] In some embodiments, the therapeutic dose of the agent may range from about 0.0001 to 100 mg / kg, more typically 0.01 to 5 mg / kg of host body weight. For example, the dose may be 1 mg / kg body weight or 10 mg / kg body weight or in the range of 1 to 10 mg / kg. Exemplary treatment regimes involve administration once every two weeks or once a month or once every 3 to 6 months. The therapeutic agent of the invention is usually administered multiple times. The interval between single doses can be weekly, monthly or yearly. The interval can also be irregular, as indicated by measuring blood levels of the therapeutic agent in the patient. Alternatively, the therapeutic agent of the invention can be administered as a sustained release formulation, in which case less frequent administration is required. The dose and frequency will vary depending on the half-life of the polypeptide in the patient.

[0215] Generally, the compositions are prepared as injections, either in liquid solutions or suspensions, and solid forms suitable for dissolving or suspending in liquid vehicles prior to injection can also be prepared. The pharmaceutical compositions herein are suitable for intravenous or subcutaneous administration, either directly or after reconstitution of solid (e.g., lyophilized) compositions. The formulations can also be emulsified or encapsulated in liposomes, or microparticles such as polylactides, polyglycolides, or copolymers, to enhance adjuvant effects, as described above. Langer, Science 249:1527, 1990 and Hanes, Advanced Drug Delivery Reviews 28:97-119, 1997. The agents of the present invention can be administered in the form of depot injections or implant formulations, which can be formulated in such a way that they allow sustained or pulsatile release of the active ingredient. The pharmaceutical compositions are generally formulated as sterile, substantially isotonic, and in full compliance with all Good Manufacturing Practice (GMP) regulations of the U.S. Food and Drug Administration.

[0216] The toxicity of the antibodies and antibody constructs described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, by measuring the LD50 (the dose lethal to 50% of the population) or the LD100 (the dose lethal to 100% of the population). The dose ratio between toxicity and therapeutic effect is the therapeutic index. The data obtained from these cell culture assays and animal studies can be used in formulating a non-toxic dose range for use in humans. The dosage of the antibodies described herein is preferably within a range of circulating concentrations that includes the effective dose with little or no toxicity. The dosage can vary within this range depending on the dosage form employed and the route of administration utilized. The exact formulation, route of administration, and dosage can be selected by the individual physician in view of the patient's condition.

[0217] The compositions for administration will generally contain the antibody or other agent (e.g., another abrasive) dissolved in a pharma- ceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, such as buffered saline. These solutions are sterile and generally free of undesirable substances. These compositions may be sterilized by conventional, well-known sterilization techniques. The compositions may contain pharma- ceutically acceptable auxiliary substances as required to approximate physiological conditions (pH adjusting and buffering agents, toxicity adjusting agents, etc., e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc.). The concentration of the active agent in these formulations can vary widely and is selected primarily based on fluid volume, viscosity, body weight, etc., according to the particular mode of administration selected and the needs of the patient (e.g., Remington's Pharmaceutical Science (15th ed., 1980) and Goodman & Gillman, The Pharmacological Basis of Therapeutics (Hardman et al., eds., 1996)).

[0218] A kit comprising the active agent of the present invention and its formulation and instructions for use is also within the scope of the present invention.The kit may further comprise at least one additional reagent, such as a chemotherapeutic agent.The kit usually comprises a label indicating the intended use of the contents of the kit.As used herein, the term "label" includes any written or recorded material that is provided on or with the kit, or that otherwise accompanies the kit.

[0219] Now that the invention is fully described, it will be apparent to those skilled in the art that various changes and modifications can be made without departing from the spirit or scope of the invention. EXAMPLES

[0220] Example 1: Heterodimer formation Heterodimer formation was analyzed by non-reducing and reducing SDS-PAGE analysis to determine whether antibodies according to embodiments of the invention containing various mutations in the hinge and Fc regions, and knob-in-hole mutations, could be successfully expressed and assembled into the desired heterodimer combinations. To test this, antibody constructs were expressed in recombinant CHO cell culture. The harvested cell culture fluid was then purified by Protein A affinity chromatography and the various antibody fragments produced were analyzed. The Protein A elution pool was then analyzed on reducing and non-reducing gels to visualize the different species.

[0221] The results of these analyses are shown in Figure 2, panels A and B, Figure 3, panels A and B, and Figure 24, and show that the percentage of heterodimer formation of antibody species containing knob-in-hole mutations is superior even in the presence of effector function silencing mutations (F234A, L235A) and Fab arm exchange prevention mutations (S228P) in addition to the heavy chain sequence. As shown in Figure 25, purified CD19 constructs were evaluated to analyze the percentage of high molecular weight (HMW) and low molecular weight (LMW) species, as well as the percentage of monomers.

[0222] Example 2: Fcγ Receptor Binding by Biolayer Interferometry (BLI) Fcγ receptor-IgG interactions were analyzed on the Octet platform using Ni-NTA biosensors (ForteBio). The Ni-NTA biosensors have nickel (Ni2+)-loaded Tris-NTA from QIAGEN immobilized on the tip. The Ni-NTA binds to a HIS tag attached to a recombinant protein. In this format, the Fcγ receptor protein is loaded onto the biosensor as a ligand and subsequently bound to the IgG. Antibodies according to embodiments of the invention were investigated to analyze the degree of interaction between their Fc regions and the Fcγ receptor protein immobilized on the biosensor.

[0223] Here, the Fcγ receptor was human Fcγ receptor I / CD64 (Acro Biosystems). Antibody concentrations tested included a two-fold serial dilution series from 100 nM to 1.6 nM. The results of these studies are shown in Figure 4, Panels A-D, Figure 5, Panels A-E, Figure 6, Panels A-D, Figure 7, Panels A-E, and Figure 26, Panels A-D, and the results show that binding of silenced Fc receptor antibodies to human FcγR1 is significantly suppressed even when knob-in-hole and Fab arm exchange mutations are present in the Fc region.

[0224] Specifically, panel A of FIG. 4 shows results for a bispecific CD3×BCMA (monovalent) IgG1 antibody that does not contain a KiH mutation or a silencing mutation. The data show that the antibody interacts with the Fcγ receptor immobilized on the biosensor. Panel B of FIG. 4 shows results for the same bispecific antibody used in panel A, but now containing a silencing mutation in the CH2 domain. These results show that the presence of the silencing mutation significantly reduces the interaction between the antibody and the Fcγ receptor on the biosensor. Panel C of FIG. 4 shows results for a bispecific CD3×BCMA (monovalent) IgG1 antibody that contains a KiH mutation but does not contain a silencing mutation. These data show that the antibody interacts with the Fcγ receptor immobilized on the biosensor in a manner very similar to that observed with the antibody in panel A. Panel D of FIG. 4 shows results for the same bispecific antibody used in panel C, but now containing a silencing mutation in the CH2 domain. These results indicate that the presence of silencing mutations significantly reduces the interaction between the antibody and the Fcγ receptor on the biosensor, even when the KiH mutation is included.

[0225] Panel A of FIG. 5 shows the results for a bispecific CD3×BCMA (monovalent) IgG4 antibody that does not contain a KiH or silencing mutation, but does contain a S228P mutation to prevent Fab arm exchange. The data show that the antibody interacts with Fcγ receptors immobilized on the biosensor. Panel B of FIG. 5 shows the results for the same bispecific antibody used in Panel A, but now containing silencing mutations (F234A, L235A) in the CH2 domain. These results show that even in the presence of the S228P mutation, the presence of the silencing mutation significantly reduces the interaction between the antibody and the Fcγ receptor on the biosensor. Panel C of FIG. 5 shows the results for a bispecific CD3×BCMA (monovalent) IgG4 antibody that contains a KiH and S228P mutation, but does not contain a silencing mutation. These data show that the antibody interacts with Fcγ receptors immobilized on the biosensor in a manner very similar to that observed with the antibody in Panel A. Panel D of FIG. 5 shows results for the same bispecific antibody used in Panel C, but now containing silencing mutations (F234A, L235A) in the CH2 domain in addition to the S228P and KiH mutations. These results show that the presence of the silencing mutations significantly reduces the interaction between the antibody and the Fcγ receptor on the biosensor, even when the S228P and KiH mutations are present. Panel E shows results for a bispecific CD3×BCMA (bivalent) IgG4 antibody containing the S228P mutation, the silencing mutations F234A and L235A, and the KiH mutation in the CH3 domain. These data show that the interaction between this antibody and the Fcγ receptor immobilized on the biosensor is significantly reduced, even when the S228P and KiH mutations are present.

[0226] Panel A of FIG. 6 shows results for a bispecific CD3×PSMA (monovalent) IgG1 antibody that does not contain a KiH mutation or a silencing mutation. The data show that the antibody interacts with the Fcγ receptor immobilized on the biosensor. Panel B of FIG. 6 shows results for the same bispecific antibody used in Panel A, but now containing a silencing mutation in the CH2 domain. These results show that the presence of the silencing mutation significantly reduces the interaction between the antibody and the Fcγ receptor on the biosensor. Panel C of FIG. 6 shows results for a bispecific CD3×PSMA (monovalent) IgG1 antibody that contains a KiH mutation but does not contain a silencing mutation. These data show that the antibody interacts with the Fcγ receptor immobilized on the biosensor in a manner very similar to that observed with the antibody in Panel A. Panel D of FIG. 6 shows results for the same bispecific antibody used in Panel C, but now containing a silencing mutation in the CH2 domain. These results indicate that the presence of silencing mutations significantly reduces the interaction between the antibody and the Fcγ receptor on the biosensor, even when the KiH mutation is included.

[0227] Panel A of FIG. 7 shows the results for a bispecific CD3×PSMA (monovalent) IgG4 antibody that does not contain a KiH or silencing mutation, but does contain an S228P mutation to prevent Fab arm exchange. The data show that the antibody interacts with Fcγ receptors immobilized on the biosensor. Panel B of FIG. 7 shows the results for the same bispecific antibody used in Panel A, but now containing silencing mutations (F234A, L235A) in the CH2 domain. These results show that even in the presence of the S228P mutation, the presence of the silencing mutation significantly reduces the interaction between the antibody and the Fcγ receptor on the biosensor. Panel C of FIG. 7 shows the results for a bispecific CD3×PSMA (monovalent) IgG4 antibody that contains a KiH mutation and an S228P mutation, but does not contain a silencing mutation. These data show that the antibody interacts with Fcγ receptors immobilized on the biosensor in a manner very similar to that observed with the antibody in Panel A. Panel D of FIG. 7 shows the results for the same bispecific antibody used in panel C, but now containing silencing mutations (F234A, L235A) in the CH2 domain in addition to the S228P and KiH mutations. These results show that the presence of the silencing mutations significantly reduces the interaction between the antibody and the Fcγ receptor on the biosensor, even when the S228P and KiH mutations are present. Panel E shows the results for a bispecific CD3×PSMA (bivalent) IgG4 antibody containing the S228P mutation, the silencing mutations F234A and L235A, and the KiH mutation in the CH3 domain. These data show that the interaction between this antibody and the Fcγ receptor immobilized on the biosensor is significantly reduced, even when the S228P and KiH mutations are present.

[0228] Panel A of FIG. 26 shows the results for a bispecific CD3×CD19 (monovalent) IgG4 antibody that does not contain a KiH or silencing mutation, but does contain a S228P mutation to prevent Fab arm exchange. The data show that the antibody interacts with Fcγ receptors immobilized on the biosensor. Panel B of FIG. 26 shows the results for the same bispecific antibody used in Panel A, but now containing silencing mutations (F234A, L235A) in the CH2 domain. These results show that even in the presence of the S228P mutation, the presence of the silencing mutation significantly reduces the interaction between the antibody and the Fcγ receptor on the biosensor. Panel C of FIG. 26 shows the results for a bispecific CD3×CD19 (monovalent) IgG4 antibody that contains a KiH mutation and a S228P mutation, but does not contain a silencing mutation. These data show that the antibody interacts with Fcγ receptors immobilized on the biosensor in a manner very similar to that observed with the antibody in Panel A. Figure 26, panel D shows results for the same bispecific antibody used in panel C, but which contains silencing mutations (F234A, L235A) in the CH2 domain in addition to the S228P and KiH mutations. These results show that even when the S228P and KiH mutations are included, the presence of the silencing mutations significantly reduces the interaction between the antibody and the Fcγ receptor on the biosensor.

[0229] Taken together, the data presented in Figures 4, 5, 6, 7, and 26 demonstrate that the VH region sequence of the bispecific antibody does not affect the functional properties of the IgG4 Fc mutations described herein. Thus, the IgG4 Fc modifications described herein (S228P; F234A, L235A; T366W, T366S, L368A, and Y407V) can be performed in antibodies with different VH sequences (i.e., different binding targets) to achieve reduced Fab arm exchange (S228P), reduced effector function activity (F234A, L235A), and proper heterodimerization (T366W; T366S, L368A, and Y407V).

[0230] Example 3: Flow cytometry analysis of binding to PSMA positive and negative cells by anti-PSMA UniAbs™ Binding to PSMA-positive cells was assessed by flow cytometry (Guava easyCyte 8HT, EMD Millipore) using LNCaP cell line (ATCC:CRL-1740), 22Rv1 cell line (ATCC CRL-2505), PC3 cell line (ATCC CRL-1435) stably transfected to express human PSMA or DU-145 cell line (ATCC HTB-81). Briefly, 50,000 target cells were stained with a dilution series of purified UniAbs™ for 30 minutes at 4°C. After incubation, cells were washed twice with flow cytometry buffer (1x PBS, 1% BSA, 0.1% NaN3) and stained with goat F(ab')2 anti-human IgG conjugated to R-phycoerythrin (PE) (Southern Biotech, Cat. No. 2042-09) to detect antibody bound to the cells. After 20 min incubation at 4°C, cells were washed twice with flow cytometry buffer and mean fluorescence intensity (MFI) was measured by flow cytometry. The MFI of cells stained with secondary antibody alone was used to measure background signal, and binding of each antibody was converted to fold background. Binding to cynomolgus PSMA-positive cells was measured using the same protocol with the following modifications: target cells were derived from Freestyle 293-F cells (ThermoFisher R79007) transiently transfected to express the extracellular domain of cynomolgus PSMA. In some experiments, EC50 values ​​were calculated using GraphPad Prism 7.

[0231] Table 8 summarizes the target binding activity of the anti-PSMA heavy chain antibodies (HCAbs) described herein. Column 1 shows the clone ID of the HCAbs. Column 2 shows the binding to LNCaP cells measured as fold background MFI signal. [Table 8]

[0232] As shown in Figure 8, panels A and B, the differences in binding to cyno PSMA support the differences in the human PSMA epitopes recognized by HCAbs 346181 and 345497.

[0233] Example 4: Composition of biparatopic and bivalent anti-PSMA antibodies As shown in Table 9, anti-PSMA clone ID350123 consists of clone ID346181 sequence linked to clone ID345497 sequence with the bridging sequence GGGGSGGGGS (SEQ ID NO: 71). Clone ID350122 consists of two repeats of clone ID346181 linked by the same linker sequence. Clone ID350123 is biparatopic since it consists of two anti-PSMA domains that recognize different epitopes on PSMA. Clone ID350122 is bivalent but not biparatopic since it consists of tandems of the same anti-PSMA domain. Schematic diagrams of various triple-chain antibody-like molecules (TCAs) are shown in Figure 1, panels A-C. [Table 9]

[0234] Example 5: Multispecific antibody-mediated cell killing of PSMA-positive prostate tumor cells by T cell redirection Assays using resting T cells Target cells were seeded at 15,000 cells per well in 96-well plates and grown overnight at 37°C. After incubation, a large amount of multispecific antibodies was added together with resting human T cells at an effector to target cell ratio of 10:1 and incubated for an additional 48 or 72 hours at 37°C (48 hours for assays with LNCaP, MDA-PCa-2b and PC3-PSMA cells, 72 hours for assays with 22Rv1 cells). Cell death was measured using either the cell proliferation reagent WST-1 (Sigma catalog number: 11644807001) or flow cytometry. In some experiments, after incubation but prior to analysis of target cell viability, a small sample of each supernatant was collected and saved for analysis of cytokine production. When cell viability was analyzed with WST-1 reagent, the reagent stock was added to each well at a 1:10 dilution and incubated for 90 minutes at 37°C. The absorbance was then measured at 450 nm (reference 690 nm) and the specific lysis rate (%) was calculated.

[0235] If target cell viability was analyzed by flow cytometry, the target cells were then labeled before initiating the assay with the membrane dye DiR (ThermoFisher D12731). After incubation with T cells and antibodies, the supernatant was either saved for cytokine analysis or discarded. The wells were then washed once to collect dead tumor cells and T cells and transferred to the flow cytometry plate. The remaining attached tumor cells were trypsinized and then added to the corresponding wells of the flow cytometry plate. Dead cells were stained using Annexin V reagent and flow cytometry was performed (BD FACSCelesta) to quantify the percentage of dead tumor cells in each sample gated by DiR staining. Wells containing untreated target cells were used to normalize for spontaneous cell death. In some experiments, a negative control antibody was used consisting of the same CD3 targeting arm as the PSMAxCD3 multispecific molecule, but with the tumor targeting arm replaced by a VH specific for the HIV protein gp120.

[0236] Figure 9 shows T cell-mediated lysis of PSMA-positive cells using unstimulated T cells. Unstimulated human T cells were incubated with PSMA-expressing cells (LNCaP) and various concentrations of multispecific antibodies. Biparatopic anti-PSMAxCD3 antibody (350123xCD3) outperformed monoparatopic PSMAxCD3 antibody (346181xCD3).

[0237] Assays using pre-activated T cells Human pan-T cells were pre-activated with plate-bound OKT3 and IL-2 for 3 days, followed by an additional day of incubation in fresh IL-2. Target cells were trypsinized, loaded with Calcein-AM (ThermoFisher C3100MP), mixed with activated T cells at an E:T ratio of 20:1, and added to wells of a 96-well plate. A dilution series of different polyspecific antibodies was added, followed by 4 hours of incubation at 37°C. Supernatants were then transferred to black 96-well plates and absorbance was measured at 480nm / 520nm ex / em to quantify calcein release. Target cells incubated in the absence of T cells were used to normalize the spontaneous calcein release of intact tumor cells. Addition of 2% Triton-X to control wells containing target cells allowed the calculation of the calcein signal corresponding to maximum cell lysis. Using this value, each experimental well was reported as a percentage of maximum cell lysis. Data analysis was performed using GraphPad prism 7.

[0238] Figure 10 shows T cell-mediated lysis of PSMA-positive cells using pre-activated T cells. Pre-activated human T cells were incubated with human PSMA-expressing cells (LNCaP) and various concentrations of multispecific antibodies. Tumor cell death was measured by calcein release and normalized to spontaneous release of tumor cells in the absence of T cells. A biparatopic anti-PSMAxCD3 antibody (350123xCD3) outperformed both monoparatopic PSMAxCD3 antibodies.

[0239] Figure 11 shows that multispecific antibodies do not lyse PSMA-negative cells. Preactivated human T cells were incubated with PSMA-negative prostate cancer cells (DU145) and various concentrations of multispecific antibodies. No lysis of these cells was caused by any of the antibodies tested.

[0240] Figure 12 shows the binding of PSMAxCD3 multispecific antibodies to PSMA positive and negative cells. Multispecific anti-PSMAxanti-CD3 antibodies show binding to PSMA positive prostate tumor cells (22Rv1) but not to PSMA negative prostate tumor cells (DU145). The biparatopic molecule (350123) showed the strongest on-target cell binding.

[0241] Figure 13 shows T cell-mediated lysis of PSMA positive cells. The data in Figure 13 demonstrate that binding to PSMA via two different epitopes increases cell killing compared to a bivalent but monospecific version of the antibody.

[0242] Example 6: Monoparatopic PSMA x CD3 bispecific antibodies do not induce cytokine production compared to biparatopic PSMA x CD3 polyspecific antibodies Cytokine production was analyzed in tumor cytotoxicity assays using resting T cells. The design of these assays has been described in detail elsewhere. Supernatants were collected at the completion of the assay (after 72 h of incubation for assays using 22Rv1 cells and 48 h for all other cell lines). ELISA kits were used according to the manufacturer's protocol to detect IL-2 (Biolegend 431804) and IFNγ (Biolegend 430104). Test supernatants were diluted prior to ELISA analysis so that the levels of cytokines fell within the linear portion of the standard curve provided with each kit. In some cases, cytokines could not be detected in the test wells and values ​​were reported to be below the lower limit of quantification of the assay.

[0243] Figure 14 (Panels A, B, and C) shows T cell-mediated lysis of PSMA-positive cells and a comparison with cytokine production. Multispecific PSMAxCD3 antibodies induce T cell-mediated lysis of the PSMA-positive prostate cancer cell line LNCaP. The biparatopic molecule (350123) stimulated tumor cell killing more potently than the monoparatopic molecule (346181), but also caused the production of higher levels of the cytokines interferon gamma (IFNγ) and interleukin 2 (IL-2), as shown in panels B and C of Figure 14.

[0244] Table 10 shows T cell-mediated lysis and cytokine production against four PSMA-positive prostate tumor cell lines. PSMAxCD3 multispecific antibodies were tested in an in vitro tumor cell cytotoxicity assay using unstimulated T cells and a range of antibody doses against a panel of four PSMA-positive tumor cell lines. After 72 hours (22Rv1) or 48 hours (MDA-PCa-2b, LNCAP, PC3-PSMA), the percentage of tumor cell death was calculated and reported as EC50, and the highest killing rate achieved was also reported. Supernatants from these test wells were collected and analyzed by ELISA for the cytokines interferon gamma (IFNγ) or interleukin-2 (IL-2). The monoparatopic molecule (3461881) induced similar levels of tumor cytotoxicity against all four cell lines tested compared to the biparatopic molecule, but with a higher EC50 for cytokine production and a lower level of stimulation of maximum cytokine production in most cases. [Table 10]

[0245] Example 7: PSMAxCD3 multispecific antibodies induce T cell proliferation PSMA-positive tumor cells were seeded at 25,000 cells per well in 96-well plates and grown overnight at 37°C. Human pan-T cells (Miltenyi 130-096-535) isolated from resting PBMCs were labeled with the lineage-tracing dye CFSE according to the manufacturer's instructions (ThermoFisher C34554). 100,000 labeled pan-T cells were then added to wells containing tumor cells, followed by dilution of a series of antibodies and incubation at 37°C, 8% CO2. After 5 days of incubation, cells were gently mixed and transferred to a flow cytometry plate. Cells were pelleted and the supernatant removed before staining with anti-CD8 conjugated to APC (Biolegend 301049) and anti-CD4 conjugated to PE (Biolegend 317410) for 20 minutes on ice. Cells were then washed and resuspended in flow cytometry buffer (BD FACSCelesta) for analysis. Cells were gated by forward and side scatter, and CD4 or CD8 expression. The percentage of proliferated T cells was calculated for the entire T cell population and for CD4 and CD8 subsets, as indicated by CD4 or CD8 positive staining and low or negative CFSE signal. Flow cytometry data was analyzed using FlowJo and plotted in GraphPad Prism 7.

[0246] FIG. 15 (Panels A, B, C, and D) shows that PSMA×CD3 multispecific antibodies stimulate T cell proliferation in the presence of PSMA-positive tumor cells, and monoparatopic PSMA bispecific antibodies preferentially activate CD3 T cells. Multispecific antibodies were incubated with PSMA-expressing tumor cells and T cells labeled with the lineage tracing dye CFSE. After 5 days of incubation, T cell proliferation and the composition of expanded T cells (CD8+ vs. CD4+) were analyzed by flow cytometry. Panels A and B show the total T cell proliferation, while panels C and D show the ratio of CD8+ to CD4+ T cells in the expanded wells. The horizontal dashed line shows the CD8:CD4 ratio of unstimulated T cells, which is approximately 1:2 (actual value=0.64). The monoparatopic PSMA x CD3 bispecific antibody (346181) preferentially activates CD8 T cells (CD8:CD4 ratio after expansion is approximately 2:1), whereas the biparatopic PSMA x CD3 polyspecific antibody (350123) has less preferential activation of CD8+ T cells (CD8:CD4 ratio is approximately 1:1).

[0247] Example 8: Multispecific antibodies inhibit prostate tumor growth in xenograft models Five- to six-week-old male immunodeficient CIEA-NOG mice (Taconic) were implanted subcutaneously with 10 million 22Rv1 cells in the right lower flank and 10 million human PBMCs were added via tail vein injection 1 day after tumor implantation. The animals were treated with 100 μg of multispecific antibody or vehicle on days 1, 5, 9, and 13, starting via tail vein injection 1 day after tumor implantation. Tumor volumes were quantified using calipers and recorded for 25 days.

[0248] Figure 16 shows the results of the 22Rv1 tumor xenograft model. The biparatopic PSMAxCD3 molecule (350123) showed inhibition of 22Rv1 tumor growth in the tumor xenograft model. Three mice were tested for each treatment group, and the change in tumor volume for each animal was plotted in cubic millimeters. Animals were administered PBMCs on day 1 after tumor implantation and treated with antibodies on days 1, 5, 9, and 13. Two of the three animals treated with the multispecific antibody showed delayed tumor progression.

[0249] Example 9: Analysis of T cell activation CD69 is a cell surface marker on T cells that is upregulated upon stimulation, thereby serving as an indicator of T cell activation. In this experiment, CD69 activation was assessed under three different conditions: 1) total peripheral blood mononuclear cells (PBMCs) without BCMA coating; 2) pan T cells with BCMA coating; and 3) pan T cells without BCMA coating. PBMCs were isolated from buffy coats using Ficoll (density 1.077 g / ml), and cryopreserved PBMCs were thawed and cultured at 2 × 10 in RPMI 1640 supplemented with 10% FBS. 6 The cells were incubated at 1000 x 1000 cells / mL for 24 hours at 37° C. On day 2, pan T cells were isolated from resting PBMCs using the Miltenyi negative selection kit and the isolated cells were used in the second and third assay conditions. In the first assay condition, PBMCs were counted and plated into the assay plates.

[0250] For cells evaluated under antigen-coated conditions, 96-well plates were coated with recombinant BCMA protein (human BCMA protein, Fc tag, Acro Biosystems, Cat. No. BC7-H5254) at a concentration of 1 μg / mL, recombinant PSMA protein (recombinant human PSMA / FOLH1 protein, RND systems, Cat. No.-4234-ZN-0101) at a concentration of 1 μg / mL, or recombinant CD19 protein (human CD19 protein, His tag, Acro Biosystems, Cat. No.-CD9-H52H2) at a concentration of 10 μg / mL. Bispecific antibodies were analyzed using a 12-point dose curve with a 3-fold dilution series, with the highest dose being 300 nM. Bispecific antibodies and T cells were resuspended in RPMI 1640 supplemented with 10% FBS and incubated for 18 hours. Pan T cells were the effector cells and were plated at 100,000 cells / well.

[0251] For cells evaluated in the absence of antigen coating, bispecific antibodies were incubated with cells using a 12-point dose curve with 3-fold dilution series. 300 nM of bispecific antibody was the highest concentration tested in this assay. Samples were incubated for 18 hours at 37° C. in RPMI1640 supplemented with 10% FBS. Pan-T cells isolated from PBMCs were effector cells and were plated at 100,000 cells / well.

[0252] For all experimental conditions, cells were washed and labeled with cell surface T cell antibodies using the following antibodies: (1) CD4 positive T cells (FITC anti-human CD4 antibody), (2) CD8 positive T cells (PE anti-human CD8a antibody), (3) CD69 activation (Alexa Fluor 647 anti-human CD69 antibody) (Biolegend). Cells were then analyzed on a BD Celesta using the appropriate template to measure CD69 activation.

[0253] The results of the T cell activation studies are shown in the following figures: Figures 17-18, Figure 27 panels A-B (no BCMA antigen coating, using PBMCs); Figure 30 panels AB (no PSMA coating); and Figure 33 panels AB (no CD19 coating).

[0254] FIG. 17 is a graph showing CD4+CD69+ T cells (%) as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. In general, bispecific antibodies containing IgG1 Fc sequences showed CD4+ T cell activation at lower concentrations of bispecific antibody. Bispecific antibodies containing IgG4 Fc sequences showed CD4+ T cell activation at higher concentrations of bispecific antibody. Notably, low CD4+ T cell activation was achieved by IgG4 Fc bispecific antibodies containing PAA and KiH mutations, indicating that introduction of PAA and KiH mutations reduces BCMA-independent activation of T cells by these bispecific antibodies.

[0255] FIG. 18 is a graph showing CD8+CD69+ T cells (%) as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. As with CD4+ T cells, bispecific antibodies containing IgG1 Fc sequences showed activation of CD8+ T cells at lower concentrations of bispecific antibody. Bispecific antibodies containing IgG4 Fc sequences showed activation of CD8+ T cells at higher concentrations of bispecific antibody. Notably, low CD8+ T cell activation was achieved by IgG4 Fc bispecific antibodies containing PAA and KiH mutations, indicating that introduction of PAA and KiH mutations reduces BCMA-independent activation of T cells by these bispecific antibodies.

[0256] Panel A of FIG. 27 is a graph showing CD4+CD69+ T cells (%) as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. CD4+ T cell activation achieved by IgG4 Fc bispecific antibodies containing PAA and KiH mutations is similar to the negative control (gp120, CD3(F2B)), indicating that introduction of PAA and KiH mutations reduces BCMA-independent activation of T cells by these bispecific antibodies. Panel B of FIG. 27 is a graph showing CD8+CD69+ T cells (%) as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. As with CD4+ T cells, CD8+ T cell activation achieved by IgG4 Fc bispecific antibodies containing PAA and KiH mutations is similar to the negative control, indicating that introduction of PAA and KiH mutations reduces BCMA-independent activation of T cells by these bispecific antibodies.

[0257] Panel A of FIG. 30 is a graph showing CD4+CD69+ T cells (%) as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. The activation of CD4+ T cells achieved by IgG4 Fc bispecific antibodies containing PAA and KiH mutations is similar to the negative control (gp120, CD3(F2B)), indicating that the introduction of PAA and KiH mutations reduces PSMA-independent activation of T cells by these bispecific antibodies. Panel B of FIG. 30 is a graph showing CD8+CD69+ T cells (%) as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. As with CD4+ T cells, the activation of CD8+ T cells achieved by IgG4 Fc bispecific antibodies containing PAA and KiH mutations is similar to the negative control, indicating that the introduction of PAA and KiH mutations reduces PSMA-independent activation of T cells by these bispecific antibodies.

[0258] Panel A of FIG. 33 is a graph showing CD4+CD69+ T cells (%) as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. The activation of CD4+ T cells achieved by IgG4 Fc bispecific antibodies containing PAA and KiH mutations is much lower than that observed from other antibody constructs not containing PAA and KiH mutations, indicating that the introduction of PAA and KiH mutations reduces CD19-independent activation of T cells by these bispecific antibodies. Panel B of FIG. 33 is a graph showing CD8+CD69+ T cells (%) as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. As with CD4+ T cells, the activation of CD8+ T cells achieved by IgG4 Fc bispecific antibodies containing PAA and KiH mutations is much lower than that observed from other antibody constructs not containing PAA and KiH mutations, indicating that the introduction of PAA and KiH mutations reduces CD19-independent activation of T cells by these bispecific antibodies.

[0259] The results of antigen-coated CD8+ T cell activation using pan T cells isolated from resting PBMCs are shown in Figure 19, Figure 28 Panel B, Figure 31 Panel B, and Figure 34 Panel B. The results of antigen-coated CD4+ T cell activation using pan T cells isolated from resting PBMCs are shown in Figure 28 Panel A, Figure 31 Panel A, and Figure 34 Panel A. The antigen-coating concentration for BCMA and PSMA was 1 μg / mL, while the antigen-coating concentration for CD19 was 10 μg / mL.

[0260] FIG. 19 is a graph showing % CD8+CD69+ T cells as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. Unlike in the experiments without BCMA coating, all bispecific antibodies showed activation of CD8+ T cells at similar concentrations as the bispecific antibodies on antigen-coated cells. Notably, CD8+ T cell activation was achieved by IgG4 Fc bispecific antibodies containing PAA and KiH mutations, indicating that introduction of PAA and KiH mutations did not abrogate the CD8+ T cell activation activity of these molecules.

[0261] Panel B of Figure 28 is a graph showing % CD8+CD69+ T cells as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. Unlike in the experiments without BCMA coating, all bispecific antibodies demonstrated CD8+ T cell activation at similar concentrations as the bispecific antibodies on antigen-coated cells. Notably, CD8+ T cell activation was achieved by IgG4 Fc bispecific antibodies containing PAA and KiH mutations, indicating that introduction of PAA and KiH mutations did not eliminate the CD8+ T cell activation activity of these molecules.

[0262] Panel B of Figure 31 is a graph showing CD8+CD69+ T cells (%) as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. Unlike in the experiments without PSMA coating, all bispecific antibodies demonstrated CD8+ T cell activation at similar concentrations as the bispecific antibodies on antigen-coated cells. Notably, CD8+ T cell activation was achieved by IgG4 Fc bispecific antibodies containing PAA and KiH mutations, indicating that introduction of PAA and KiH mutations did not eliminate the CD8+ T cell activation activity of these molecules.

[0263] Panel B of Figure 34 is a graph showing CD8+CD69+ T cells (%) as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. Unlike the experiments without CD19 coating, all bispecific antibodies demonstrated CD8+ T cell activation at similar concentrations as the bispecific antibodies on antigen-coated cells. Notably, CD8+ T cell activation was achieved by IgG4 Fc bispecific antibodies containing PAA and KiH mutations, indicating that introduction of PAA and KiH mutations did not eliminate the CD8+ T cell activation activity of these molecules.

[0264] Panel A of Figure 28 is a graph showing % CD4+CD69+ T cells as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. Unlike in the experiments without BCMA coating, all bispecific antibodies demonstrated CD4+ T cell activation at similar concentrations as the bispecific antibodies on antigen-coated cells. Notably, CD4+ T cell activation was achieved by IgG4 Fc bispecific antibodies containing PAA and KiH mutations, indicating that introduction of PAA and KiH mutations did not eliminate the CD4+ T cell activation activity of these molecules.

[0265] Panel A of Figure 31 is a graph showing CD4+CD69+ T cells (%) as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. Unlike in the experiments without PSMA coating, all bispecific antibodies showed CD4+ T cell activation at similar concentrations as the bispecific antibodies on antigen-coated cells. Notably, CD4+ T cell activation was achieved by IgG4 Fc bispecific antibodies containing PAA and KiH mutations, indicating that introduction of PAA and KiH mutations did not eliminate the CD4+ T cell activation activity of these molecules.

[0266] Panel A of Figure 34 is a graph showing CD4+CD69+ T cells (%) as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. Unlike the experiments without CD19 coating, all bispecific antibodies showed CD4+ T cell activation at similar concentrations as the bispecific antibodies on antigen-coated cells. Notably, CD4+ T cell activation was achieved by IgG4 Fc bispecific antibodies containing PAA and KiH mutations, indicating that introduction of PAA and KiH mutations did not eliminate the CD4+ T cell activation activity of these molecules.

[0267] The results of CD8+ T cell activation without antigen coating using pan T cells isolated from resting PBMCs are shown in Figure 20, Figure 29, Panel B, Figure 32, Panel B, and Figure 35, Panel B. The results of CD4+ T cell activation without antigen coating using pan T cells isolated from resting PBMCs are shown in Figure 29, Panel A, Figure 32, Panel A, and Figure 35, Panel A.

[0268] Figure 20 is a graph showing % CD8+CD69+ T cells as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. These results show that CD69 activation in CD8+ T cells is BCMA-dependent for all bispecific antibody molecules tested.

[0269] Panels A and B of Figure 29 are graphs showing % CD4+CD69+ T cells and % CD8+CD69+ T cells, respectively, as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. These results show that CD69 activation in CD4+ and CD8+ T cells is BCMA-dependent for all bispecific antibody molecules tested. CD69 activation was slightly increased in both CD4+ and CD8+ T cells at higher concentrations of bispecific antibody constructs that did not contain a silencing mutation.

[0270] Panels A and B of Figure 32 are graphs showing % CD4+CD69+ T cells and % CD8+CD69+ T cells, respectively, as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. These results demonstrate that CD69 activation in CD4+ and CD8+ T cells is PSMA-dependent for all bispecific antibody molecules tested.

[0271] Panels A and B of Figure 35 are graphs showing CD4+CD69+ T cells (%) and CD8+CD69+ T cells (%), respectively, as a function of bispecific antibody concentration for the bispecific antibody constructs indicated in the legend. These results show that CD69 activation in CD4+ and CD8+ T cells is CD19-dependent for all bispecific antibody molecules tested. CD69 activation was slightly increased in both CD4+ and CD8+ T cells at higher concentrations of bispecific antibody constructs that did not contain a silencing mutation.

[0272] Example 10: Lysis of Tumor Cells Anti-CD3 x anti-BCMA bispecific antibodies were assayed for their ability to kill three different BCMA+ tumor cells and one BCMA-negative cell line through redirection of activated primary T cells. In this experiment, tumor cells and activated pan-T cells were mixed at an E:T ratio of 10:1 with addition of bispecific antibodies. The results are shown in Figure 21, panels A-D. Panel A shows the killing of RPMI-8226 cells, panel B shows the killing of NCI-H929 cells, panel C shows the killing of U-266 cells, and panel D shows the killing of negative control K562 cells. The x-axis shows the concentration of antibody used and the y-axis shows the lysis (%) of tumor cells 6 hours after addition of antibody.

[0273] Resting human T cells were cultured with various tumor cell lines and increasing doses of anti-CD3 x anti-BCMA bispecific antibodies, and the level of IL-2 cytokine release was measured. Panel A of Figure 22 shows IL-2 release stimulated by RPMI-8226 cells. Panel B of Figure 22 shows IL-2 release stimulated by NCI-H929 cells. Panel C of Figure 22 shows IL-2 release stimulated by U-266 cells. Panel D of Figure 22 shows IL-2 release stimulated by negative control K562 cells.

[0274] Resting human T cells were cultured with various tumor cell lines and increasing doses of anti-CD3 x anti-BCMA bispecific antibodies, and the level of IFN-γ cytokine release was measured. Panel A of Figure 23 shows IFN-γ release stimulated by RPMI-8226 cells. Panel B of Figure 23 shows IFN-γ release stimulated by NCI-H929 cells. Panel C of Figure 23 shows IFN-γ release stimulated by U-266 cells. Panel D of Figure 23 shows IFN-γ release stimulated by negative control K562 cells.

[0275] While preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Those skilled in the art will recognize numerous variations, changes, and substitutions without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in the practice of the invention. It is intended that the following claims define the scope of the invention, and that methods and structures within the scope of these claims, and their equivalents, are covered thereby.

Claims

1. 1. An isolated multispecific antibody, comprising: a first binding moiety having binding specificity for CD3, comprising a first heavy chain polypeptide subunit comprising a heavy chain variable domain comprising a CDR1 sequence comprising the sequence of SEQ ID NO:36, a CDR2 sequence comprising the sequence of SEQ ID NO:37, and a CDR3 sequence comprising the sequence of SEQ ID NO:38, and a first light chain polypeptide subunit comprising a light chain variable domain comprising a CDR1 sequence comprising the sequence of SEQ ID NO:39, a CDR2 sequence comprising the sequence of SEQ ID NO:40, and a CDR3 sequence comprising the sequence of SEQ ID NO:41; and A second heavy chain polypeptide subunit comprising a heavy chain variable domain. Including, the first heavy chain polypeptide subunit further comprises a mutated human IgG4 constant region comprising the mutations S228P, F234A, L235A, and T366W; the second heavy chain polypeptide subunit comprises a mutated human IgG4 constant region comprising the mutations S228P, F234A, L235A, T366S, L368A, and Y407V; Isolated multispecific antibodies.

2. 2. The isolated multispecific antibody of claim 1, wherein the mutated human IgG4 constant region of the second heavy chain polypeptide subunit is deleted for the CH1 domain.

3. 3. The isolated multispecific antibody of claim 1 or 2, wherein the mutated human IgG4 constant region of the first heavy chain polypeptide subunit comprises the sequence of SEQ ID NO: 73 or 55 and the mutated human IgG4 constant region of the second heavy chain polypeptide subunit comprises the sequence of SEQ ID NO: 72 or 54.

4. the heavy chain variable domain of the first binding moiety comprises a sequence having at least 95% identity to SEQ ID NO:42; the light chain variable domain of the first binding moiety comprises a sequence having at least 95% identity to SEQ ID NO: 43; An isolated multispecific antibody according to any one of claims 1 to 3.

5. The heavy chain variable domain of the first binding moiety comprises the sequence of SEQ ID NO:42; The light chain variable domain of the first binding moiety comprises the sequence of SEQ ID NO: 43; 5. The isolated multispecific antibody of claim 4.

6. 6. The isolated multispecific antibody of any one of claims 1 to 5, wherein the second binding moiety comprises a single heavy chain variable region in a monovalent or bivalent configuration.

7. 7. The isolated multispecific antibody of claim 6 , wherein the first light chain polypeptide subunit of the first binding moiety comprises a light chain constant domain.

8. A pharmaceutical composition comprising a multispecific antibody according to any one of claims 1 to 7.

9. A polynucleotide encoding the multispecific antibody of any one of claims 1 to 7.

10. A vector comprising the polynucleotide of claim 9.

11. A cell comprising the vector of claim 10.

12. A method for producing a multispecific antibody according to any one of claims 1 to 7, comprising growing the cells of claim 11 under conditions permissive for expression of the multispecific antibody and isolating the multispecific antibody from the cells.

13. A medicament for treatment comprising an effective dose of a multispecific antibody according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 8.

14. 13. Use of a multispecific antibody according to any one of claims 1 to 7 in the preparation of a medicament for the treatment of a disease or disorder in an individual in need thereof.

15. A medicament for treating a disease or condition characterized by expression of CD19, comprising an effective dose of a multispecific antibody according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 8.

16. The pharmaceutical composition of claim 15, wherein the disease or condition is diffuse large B-cell lymphoma (DLBCL).

17. The pharmaceutical composition according to claim 15, wherein the disease or condition is acute lymphoblastic leukemia (ALL).

18. The pharmaceutical composition of claim 15, wherein the disease or condition is non-Hodgkin's lymphoma (NHL).

19. The pharmaceutical composition according to claim 15, wherein the disease or condition is systemic lupus erythematosus (SLE).

20. The pharmaceutical composition according to claim 15, wherein the disease or condition is rheumatoid arthritis (RA).

21. The pharmaceutical composition according to claim 15, wherein the disease or condition is multiple sclerosis (MS).

22. A kit for treating a disease or disorder in an individual in need thereof comprising a multispecific antibody according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 8, and instructions for use.

23. 23. The kit of claim 22, further comprising at least one additional reagent.

24. 24. The kit of claim 23, wherein the at least one additional reagent comprises a chemotherapeutic agent.

25. A bispecific three-chain antibody-like molecule that binds to human CD3 and human CD19, (i) a first polypeptide subunit comprising the amino acid sequence of SEQ ID NO:49; (ii) a second polypeptide subunit comprising the amino acid sequence of SEQ ID NO:56; and (iii) a third polypeptide subunit comprising the amino acid sequence of SEQ ID NO:

67. Including, the first polypeptide subunit and the second polypeptide subunit together form a first binding moiety that binds to human CD3; A bispecific three-chain antibody-like molecule.

26. 26. The bispecific three-chain antibody-like molecule of claim 25, wherein the first polypeptide subunit comprises a light chain.

27. 26. The bispecific three-chain antibody-like molecule of claim 25, wherein the second polypeptide subunit comprises a heavy chain.

28. 26. The bispecific three-chain antibody-like molecule of claim 25, wherein the third polypeptide subunit comprises a monovalent heavy chain.

29. 29. The bispecific three-chain antibody-like molecule of claim 28, wherein the monovalent heavy chain comprises the variable region of the heavy chain only in a monovalent configuration.

30. 29. The bispecific three-chain antibody-like molecule of claim 28, wherein the monovalent heavy chain lacks a CH1 domain.

31. A bispecific three-chain antibody-like molecule that binds to human CD3 and human CD19, (i) a first polypeptide subunit comprising the amino acid sequence of SEQ ID NO:49; (ii) a second polypeptide subunit comprising the amino acid sequence of SEQ ID NO: 75; and (iii) a third polypeptide subunit comprising the amino acid sequence of SEQ ID NO:

78. Including, the first polypeptide subunit and the second polypeptide subunit together form a first binding moiety that binds to human CD3; A bispecific three-chain antibody-like molecule.

32. 32. The bispecific three-chain antibody-like molecule of claim 31 , wherein the first polypeptide subunit comprises a light chain.

33. 32. The bispecific three-chain antibody-like molecule of claim 31 , wherein the second polypeptide subunit comprises a heavy chain.

34. 32. The bispecific three-chain antibody-like molecule of claim 31 , wherein the third polypeptide subunit comprises a monovalent heavy chain.

35. 35. The bispecific three-chain antibody-like molecule of claim 34, wherein the monovalent heavy chain comprises the variable region of the heavy chain only in a monovalent configuration.

36. 35. The bispecific three-chain antibody-like molecule of claim 34, wherein the monovalent heavy chain lacks a CH1 domain.

37. A human monoclonal IgG4 bispecific antibody, (i) a first binding arm that binds to human CD3; and (ii) a second binding arm that binds to human CD19. Including, the first binding arm comprises a first heavy chain comprising the amino acid sequence of SEQ ID NO:56 and a light chain comprising the amino acid sequence of SEQ ID NO:49; the second binding arm comprises a monovalent second heavy chain comprising the amino acid sequence of SEQ ID NO:67; antibody.

38. 38. The human monoclonal IgG4 bispecific antibody of claim 37, wherein the second binding arm does not comprise a light chain.

39. 38. The human monoclonal IgG4 bispecific antibody of claim 37, wherein the monovalent second heavy chain comprises the variable region of only the heavy chain in a monovalent configuration.

40. 38. The human monoclonal IgG4 bispecific antibody of claim 37, wherein the monovalent second heavy chain lacks a CH1 domain.

41. A human monoclonal IgG4 bispecific antibody, (i) a first binding arm that binds to human CD3; and (ii) a second binding arm that binds to human CD19. Including, the first binding arm comprises a first heavy chain comprising the amino acid sequence of SEQ ID NO:75 and a light chain comprising the amino acid sequence of SEQ ID NO:49; the second binding arm comprises a monovalent second heavy chain comprising the amino acid sequence of SEQ ID NO: 78; antibody.

42. 42. The human monoclonal IgG4 bispecific antibody of claim 41, which does not comprise a second binding arm light chain.

43. 42. The human monoclonal IgG4 bispecific antibody of claim 41 , wherein the monovalent second heavy chain comprises the variable region of only the heavy chain in a monovalent configuration.

44. 42. The human monoclonal IgG4 bispecific antibody of claim 41 , wherein the monovalent second heavy chain lacks a CH1 domain.

Images